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Patients with chronic kidney disease (CKD) are prone to develop an accelerated vascular aging 
phenotype characterized by vascular calcification (VC), a major culprit of cardiovascular 
complications and premature death. While VC has been recognized as an active 
pathophysiologic process with involvement of specific mediators and effectors, the co-
existence of traditional risk factors (i.e., high age, diabetes, hypertension, dyslipidemia), 
inflammaging stimuli and pharmacological interventions (e.g., phosphate binders, warfarin and 
statin therapy) adds to the complexity of the course and consequences of different types of VC 
(e.g., intima and media VC, micro- and macrocalcification) in the context of CKD. This work 
attempts to further explore the prognostic value, predictive markers as well as collateral 
therapeutic consequence of VC in uremic milieu.  
Study I explores the associations of the composites of coronary artery calcium (CAC) score, 
i.e., CAC density and CAC volume, with mortality risk in patients with CKD stage 5 (CKD 
G5). We found that while mortality risk increases with higher CAC score and CAC volume, 
CAC density shows an inverse-J shaped pattern, with the crude mortality rate being highest in 
the middle tertile of CAC density.  
Study II evaluates the overlapping presence of aortic valve calcium (AVC) and CAC and the 
prognostic value of AVC in CKD5 patients. We found a more common overlap of AVC and 
CAC in CKD G5 than that observed in general population. High AVC score is associated with 
increased all-cause mortality independent of presence of CAC, traditional risk factors and 
inflammation. 
Study III investigates phenotypic factors associated with the presence of biopsy-verified media 
VC in CKD G5 patients using the relaxed linear separability feature selection model. We 
identified through a mapping and ranking process, 17 features including novel biomarkers and 
traditional risk factors that can differentiate patients with media VC from those without. These 
results, if confirmed, may inform future investigations on media VC without the need of arterial 
biopsies. 
Study IV assesses the association of commonly prescribed phosphate binder sevelamer with 
gut microbial metabolites in CKD G5 patients. We found that sevelamer therapy associates 
with increased gut-derived uremic toxins and poor vitamin K status, suggesting potential trade-
offs of sevelamer therapy in CKD.   
Study V explores the plausible association between plasma dephosphorylated-uncarboxylated 
matrix Gla-protein (dp-ucMGP, a circulating marker of functional vitamin K deficiency), VC 
and mortality in CKD G5 patients. We found an independent association between high dp-
ucMGP levels and increased mortality risk that is not modified by presence of CAC and AVC 
in CKD G5.   
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1.1 CHRONIC KIDNEY DISEASE AND PREMATURE VASCULAR AGING 
Patients with chronic kidney disease (CKD) are characterized by an accelerated aging process, 
including multiple cardiovascular complications, muscle wasting, osteoporosis and frailty 
[1,2]. In particular, the arterial vasculature in CKD patients undergoes changes typical of aging 
and atypical of the chronological age [2,3]. This premature vascular aging phenotype, 
accompanied by progressive vascular calcification (VC), along with chronic inflammation, 
persistent oxidative stress and deficient anti-aging systems [2], is considered as a major culprit 
of unfavorable cardiovascular complications in CKD.  
Current clinical strategies aiming at counteracting VC are focused on controlling 
atherosclerosis and CKD - mineral bone disorders (CKD-MBD), using among others statin 
therapy, inhibition of calcium-phosphate depositions by employing phosphate binders, and 
calcimimetics, calcitriol, or vitamin D analogues while while vitamin K, magnesium, and 
crystallization inhibitors (e.g., pyrophosphate and sodium thiosulfate) are also being 
considered. Established and some emerging treatments have been evaluated in interventional 
studies, yet results are inconclusive and it remains ambiguous whether they are efficient in 
ameliorating VC progression in patients with CKD [4]. Additionally, although the unraveling 
of molecular targets of VC (e.g., intravenous myo-inositol hexaphosphate [5], serum- and 
glucocorticoid-inducible kinase 1 inhibitor [6] and apabetalone [7]) has brought either 
preclinical or clinical evidence for potential novel therapies of VC, no pharmaceutical 
treatments have so far proven to avert or thoroughly reverse VC progression in CKD.  
Recent data from the European Renal Association-European Dialysis and Transplant 
Association (ERA-EDTA) Registry on trends of excess mortality - in relation to the general 
population - among 280,075 adult patients who started kidney replacement therapy (KRT) 
between 2002 and 2015 indicate an overall improvement of survival that was most prominent 
in dialysis patients who showed a decrease in excess mortality risk per five years by 28% for 
atheromatous cardiovascular disease (CVD), 10% for non-atheromatous CVD and 10% for 
infections [8]. This may reflect developments in dialysis treatment as well as the introduction 
and implementation of guideline-recommended treatments to improve cardiovascular health in 
the CKD population. However, the implications and impact of these newer treatment strategies 
on ameliorating cardiovascular complications including vascular aging (e.g., atheroma and 
arteriosclerosis) in this population are not fully deciphered.  
It is plausible that the concurrence of traditional risk factors, CKD-MBD, gut dysbiosis, 
persistent oxidative stress, uremic inflammation and cellular senescence involved in the 
pathological VC process, together with the diverse consequent forms of VC may bewilder its 
actual clinical relevance and importance as a therapeutic target in the context of CKD. More 
profound knowledge of phenotypic features, clinical relevance and prognostic value of VC 
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remains to be clarified in this enigmatic scenario to develop and orientate efficient preventive 
and therapeutic strategies to counteract VC.  
1.2 VASCULAR CALCIFICATION IN CKD - A COMPLEX SCENARIO  
In CKD, premature VC can occur in different vascular layers (i.e., intima and media VC) 
distributed at divergent anatomical sites (i.e., different vascular trees) with distinct nature (i.e., 
microcalcification and macrocalcification). The divergent forms of VC obstruct the utilization 
of VC in risk prediction and adds complexity to its role in risk prediction and disease prognosis 
in clinical settings. The development of Agatston scoring as a semi-quantitative measure of 
coronary artery calcium (CAC) [9] has allowed screening, quantification and follow-up of large 
study groups to compute the presence and progression of atherosclerotic calcification, which 
was found to be a predictor of future CVD events beyond traditional Framingham risk score 
(FRS) [10]. However, the appropriateness of upweighting CAC for density has been questioned 
with emerging data indicating a disparate trajectory of CAC volume and density in CVD risk 
prediction in different populations [11–15].  
Moreover, the distribution of intima and media calcification may differ in different artery 
segments, e.g., with more limited media calcification but more prominent atherosclerotic 
plaques in coronary arteries. Given the possible profound media calcification in CKD, 
quantification of calcification at coronary artery sites represented by CAC may fail to give a 
full coverage of VC burden in CKD population. Since current imaging techniques are not able 
to differentiate between intima and media calcification, and it is uncertain whether intimal and 
medial layers of calcification are of equal weight in risk prediction, the prognostic value of 
CAC scoring of atherosclerotic plaque in CKD may not be as representative as observed in the 
general population. In addition, the nature of atherosclerotic calcification, i.e., micro- and 
macrocalcification, and the role of inflammation in the evolution of these two entities, largely 
remains to be illuminated. Taken together, the persistent uremic inflammation concomitant 
with other traditional and non-traditional risk factors may complicate the role of atherosclerosis 
in risk prediction, and the unequal susceptibility of intima and media calcification in different 
vascular segments could further challenge a holistic evaluation of VC in the context of CKD. 
1.3 CLINICAL RELEVANCE AND PROGNOSTIC VALUE OF VC COMPONENTS   
The presence of VC is a common outcome of different types of vessel wall injury resulting 
from numerous stimuli and cellular insults, such as oxidative stress and inflammation. The 
consequent diverse forms of VC might be considered as a reflection of the heterogeneous VC 
pathogenesis on a cellular level. In the clinical setting, it is therefore crucial to differentiate the 
phenotypic features and clinical spectrums of VC, as to better understand the clinical relevance 
of VC and to improve interventional strategies. 
In the early stages of atherosclerosis, initial hydroxyapatite deposition in response to pro-
inflammatory stimuli induces the formation of microcalcification nuclei, which can in turn 
exacerbate the progression of inflammation and calcium precipitation, causing propagation of 
vessel impairment [16]. Ultimately, this vicious interplay promotes plaque rupture as a result 
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of the progressive thinning of the fibrous cap and the detrimental mechanical effect of 
microcalcification [17]. Nevertheless, if an adaptive and repairing response prevails, vascular 
smooth muscle cells (VSMCs) would undergo osteogenic phenotypic differentiation and 
mineralization, prompting the formation of macrocalcification, which can stabilize the plaque 
by acting as a barrier restricting the spread of inflammation [16]. Postmortem analysis of 
coronary artery biopsies from victims of acute myocardial infarction presented more extensive 
VC than those from non-cardiac victims, and the extent of VC was less advanced in unstable 
than in stable plaques, suggesting an inverse correlation between calcium deposition and cap 
inflammation [18].  
From a histological perspective, calcifications are defined as microcalcification (³0.5 µm, 
typically <15 µm in diameter), speckled calcification (£2 mm), collectively referred to as 
“microcalcification” or spotty calcification based on the granular pattern of calcium deposition, 
fragmented calcification (2-5 mm), and diffuse calcification (³5 mm segment of continuous 
calcium) or “macrocalcification” based on the sheet-like conformation of the calcified tissue. 
The last three histological classifications correspond to the radiographic categories as speckled, 
fragmented, and diffuse calcification, respectively. The earlier stages of microcalcifications or 
spotty calcification may be associated with risks of plaque rupture. In cases of sudden coronary 
death, 65% of acute plaque ruptures were characterized by exclusive speckled calcification and 
over 50% of thin-cap fibro atheroma showed either an absence of calcification or speckled 
calcification by computed tomography (CT) imaging [19]. Additionally, routine lipid lowering 
strategies (i.e., statin use) targeting CAC have yielded conflicting results, with previous studies 
suggesting an impact on CAC regression and contemporaneous data indicating rather the 
opposite [20–22]. Of note, while CAC progression might be attributed to plaque development 
into a more unstable morphology with accumulative spotty and focal calcifications, CAC 
progression in the context of lipid lowering treatment might be pertinent to a shift towards 
plaque stabilization with a more stable fibro-calcific morphology [23].  
This CAC paradox may be attributed to the limitation of conventional CT whereby micro-
calcification nodules smaller than 15 µm and speckled calcification <0.5 mm are undetectable 
and classified as “absent” in the radiographic examination, which may also partially explain 
the inconclusive results regarding the predictive value of CAC components (i.e. CAC density 
and volume). While CAC volume was found to be positively and CAC density negatively 
associated with CVD events across all levels of CAC volume, as well as multiple strata of other 
risk factors in general population [13], Bellasi et al. [14] reported a positive association among 
plaque density and risk of all-cause mortality in hemodialysis (HD) patients, implying that high 
density calcium by conventional CT does not illuminate a favorable plaque stabilization in the 
context of CKD. The prognostic value of CAC components in uremia is further explored in 
Study I. The prevalence of calcification at different vascular sites and the prognosis of aortic 
valve calcium (AVC) is further investigated in Study II. 
Aside from intima calcification and atherosclerosis, patients with CKD display a typical pattern 
with media calcification characterized by pathological deposition of hydroxyapatite in the 
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medial layer of the arteries [24]. Media calcification is centered around VSMC calcification 
that shares similarities with developmental osteogenesis/chondrogenesis [25]. Under 
physiological conditions, an endogenous defensive system would protect VSMCs from 
phenotypic transdifferentiation and ectopic calcification. Multiple lines of evidence indicate 
that the uremic milieu (e.g. uremic toxins retention and other pathological cellular stress) 
triggers key pathways of VSMCs calcification and induces tissue damage via various 
modifications in proteins and DNA [26–29]. The inhibitory defense pathways, which tend to 
be suppressed in CKD by factors such as hyperphosphatemia, hypercalcemia, 
hyperparathyroidism and hypomagnesemia, with coexistence of inflammation and oxidative 
stress,  are further challenged to counteract the VC burden [28,30]. Media calcification causes 
arterial stiffness, a hallmark of early vascular aging (EVA), and the extent of media 
calcification can be taken as an estimation of biological vascular age. This is in line with the 
notion that CKD may serve as a clinical model of EVA whereby cellular senescence is possibly 
involved in the VC process [31].  
As mentioned previously, media calcification also accounts for cardiovascular comorbidity and 
mortality in CKD, similar with intima calcification. However, the exact causality between 
media calcification and poor clinical outcome remains to be established as most of the clinical 
research conclusions are based on observational studies. Well-designed prospective follow-up 
studies are warranted to illustrate whether the progression of media calcification is crucial in 
determining clinical outcomes. However, such studies have been hampered by the lack of 
specific and valid imaging and quantification techniques of media calcification. Clinical 
investigations have focused most often on coronary arteries and the aortic arteries, where both 
media and atherosclerotic calcification can occur in parallel.  
While carotid-femoral pulse wave velocity (PWV) has been considered as an established 
marker of arterial stiffening [32,33] and a reflection of media calcification, it is a functional 
measurement rather than a direct quantification of calcification. Precise quantification of media 
calcification can only be achieved from arterial beds exclusively devoid of atherosclerosis, 
where media calcification takes place with high sensitivity. The research exploration of 
mammograms in breast arteries has provided new insights into the detection of media 
calcification as atherosclerosis does not occur in breast arteries [34]. According to 
mammographic data, it was recently shown that the progression of media calcification in breast 
arteries accelerated significantly in advanced CKD, and diminished to control levels after 
kidney transplantation [34]. While this might indeed provide a novel and easy method to 
evaluate the presence and progression of media calcification, these studies were conducted in 
a small sample of female patients, and the validity in large-size cohorts of CKD patients 
including men remains to be testified. In fact, no fundamental breakthroughs have been made 
in the diagnosis (i.e., visualization of the extent and severity of media calcification) or 
therapeutics that directly target media VC.  
Hence, aside from expanding mechanistic knowledge in preclinical studies, advanced data 
analysis methodology and machine-learning algorithms including integrating biomarkers, 
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mechanistic and imaging data so as to predict and to diagnose the presence of media 
calcification and more importantly, to discover novel therapeutic targets, are urgently needed. 
In Study III, we attempt to explore the predictive features of media calcification using an 
advanced statistical model. 
1.4 THERAPEUTIC STRATEGIES, GUT MICROBIAL METABOLISM AND VC 
Current clinical strategies targeting VC or aiming at improving clinical outcomes linked to VC, 
range from lipid-lowering drugs, management of CKD-MBD, to inhibition of calcium 
phosphate deposition. Hyperphosphatemia, one of the most common metabolic disorders in 
CKD, seems to be amplified in advanced CKD and associates with adverse clinical outcome 
across all stages of the disease [35,36]. Even without predominant hyperphosphatemia and 
hypercalcemia, the phosphate and calcium load tends to drive VC in both CKD and in the 
general population [37]. Also, in combination with elevated parathyroid hormone levels and 
frequent use of calcitriol, phosphate overload and hyperphosphatemia may further induce 
development of kidney and parathyroid glands resistance to fibroblast growth factor 23 
(FGF23), eventually resulting in a paradigm of hyperphosphatemia, excessive FGF23 levels 
and secondary hyperparathyroidism in advanced CKD. The direct or indirect role of FGF23 in 
VC development has been discussed and it remains to be determined whether FGF23 acts as a 
protective or detrimental factor in uremic calcification [38–41]. Targeting FGF23 alone is 
clearly not an optimal strategy to combat VC as the pathophysiologic trajectory is still elusive. 
Phosphate binders targeting hyperphosphatemia, which also reduce FGF23 levels, hence 
become a cornerstone in improving clinical outcome in uremic patients.  
Currently, both sevelamer hydrochloride and sevelamer carbonate are used in clinical practice 
and are first-line phosphate binders in many dialysis units [42]. Despite not being fully 
established, some randomized clinical trials suggested that compared with calcium-containing 
phosphate binders,  sevelamer ameliorated VC progression and conferred a survival benefit in 
HD patients [43,44]. However, sevelamer treatment may have trade-offs. First of all, both 
experimental and clinical data have indicated that sevelamer may bind essential nutrients, such 
as vitamin D and K [45–47]. Secondly, gastrointestinal symptoms are common among 
sevelamer users, albeit the underlying pathophysiology is poorly addressed. Thirdly, 
depositions of mucosal sevelamer crystals along the gastrointestinal tract [48–50] can alter the 
influx of minerals and nutrients and influence the transit time in the colon. Altogether, they 
may induce gut dysbiosis, ultimately resulting in an increased generation of toxins originating 
from protein and choline fermentation. It is worth noting that like sevelamer, many 
pharmaceutical agents often have gastrointestinal side effects, yet the role of the gut 
microbiome in these processes is rarely examined. Along the recent increased awareness of 
drug-microbiome interactions [51], the association between sevelamer use and gut microbial 
metabolism is explored in Study IV. 
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1.5 VITAMIN K AND VC 
The role for vitamin K in VC has been fairly well established in preclinical studies, mainly 
through carboxylation of vitamin K-dependent protein matrix Gla protein (MGP), which is 
primarily synthesized and secreted by VSMCs [52]. Preceding work on MGP biology was 
conducted in a knockout mouse model, where MGP-deficient mice developed extensive 
calcification both in arteries and cartilage within two months [53]. MGP inhibits VC in vivo 
[53–55], possibly by a direct binding with hydroxyapatite in the arterial walls [56] and by a 
downregulation of the activation of bone morphogenetic proteins [57,58]. Activation of MGP 
requires two post-translational modifications, including serine phosphorylation and γ-
glutamate carboxylation [59,60]. Vitamin K serves as a cofactor of MGP carboxylation by 
converting glutamate residues into γ-carboxyglutamate [59,61]. Vitamin K deficiency, thus 
limits the carboxylation of MGP in VSMCs, leading to a subsequent high secretion of 
dephosphorylated uncarboxylated MGP (dp-ucMGP). High circulating dp-ucMGP levels, as a 
marker of functional vitamin K deficiency, have been linked with mortality in various study 
subjects, including patients with CVD [62–64], CKD [65–67], diabetes[68], as well as in the 
general population [69,70]. Whether this association can be attributed to its role in inhibiting 
VC is being debated. The association between vitamin K status and VC from observational 
studies are equivocal [71–75].  Results from the recent K4Kidneys trial revealed that 12-month 
vitamin K2 supplementation generally failed to improve parameters of vascular health in 
patients with CKD [76]. Given the multifaceted etiology of VC, it is plausible that one single 
intervention is insufficient to rescue VC process and the exact weight of vitamin K in VC 
progression is to be elucidated. 
In addition, a large body of epidemiological studies suggests that vitamin K is involved in age-
related disease phenotypes other than vascular health. Results from the he Health, Aging and 
Body Composition Study (Health ABC) indicated that vitamin K deficiency was associated 
with diminished lower-extremity function over 4-5 years of follow-up [77]. The prospective 
Longitudinal Aging Study Amsterdam (LASA) cohort study showed that a lower baseline 
vitamin K status (indicated by higher dp-ucMGP levels), was associated with a higher frailty 
index score among the elderly with 13-year follow-up [78]. Though the underlying mechanism 
behind these associations has not been clearly illustrated, the epidemiological evidence 
suggests a beneficial role of vitamin K above its role as a nutritional supplement or remedy. 
Vitamin K deficiency is prevalent in CKD and progresses with the decline of renal function 
[65,74,79,80]. Given the role of vitamin K insufficiency in VC and age-related disease, it would 
be interesting to evaluate the association between vitamin K status, VC, and overall clinical 







2 RESEARCH AIMS 
The overall aim of the present thesis is to expand our understanding of risk factors and clinical 
relevance of vascular calcification in CKD. 
More specifically, the objectives were to: 
• Investigate the prognostic value of atherosclerotic calcification, represented by CAC 
density and CAC volume, and the role of AVC in risk stratification in patients with 
advanced CKD (Study I and II) 
 
• Identify and characterize risk factors associated with histologically verified media 
calcification in arterial biopsies obtained from patients with advanced CKD (Study III) 
 
• Study the possible link between sevelamer use and gut microbial metabolism in patients 
with advanced CKD (Study IV) 
 
• Explore the plausible associations between vitamin K deficiency, vascular calcification, 


















3 PATIENTS AND METHODS 
The work presented in this thesis has been conducted using data from three cohorts of patients 
that have been/are collected and coordinated by the Division of Renal Medicine, Karolinska 
University Hospital at Huddinge, Stockholm, Sweden and from one cohort of patients at 
University Hospital Leuven, Belgium. At the Karolinska University Hospital, Huddinge, 
patients with CKD were enrolled in the following studies: the prospective MIA study of 
incident CKD stage 5 (CKD G5) patients started in 1994 with ongoing recruitment and follow-
up; MIMICK 2 study of prevalent peritoneal dialysis (PD) patients initiated in 2008 with a 
median follow-up of 32 months; and the prospective Kärltx (RTx-LD) study of living donor 
kidney transplant recipients commenced in 2009 with ongoing patient recruitment and follow-
up. At University Hospital Leuven, data were obtained from kidney transplant recipients who 
had consented to participate in a prospective kidney allograft biopsy program. Hence, the 
patient material was processed using post hoc analysis of collected data. The number of patients 
included and the primary parameters or clinical endpoints in the different sub-studies of this 
thesis are summarized in Table 1. 
Table 1. Cohort information and main investigation in each study. 
 Study I Study II Study III Study IV Study V 
N 296 259 152 423 493 
Cohort      
   MIA* 107 94 - - 270 
   MIMICK2* 55 53 - - 82 
   Kärltx * 134 112 152 76 141 
  Leuven cohort # - - - 347 - 
Age, years 
(median) 
55 55 46 54 55 

























* Cohorts based and established at Karolinska University Hospital, Stockholm, Sweden; #Patients from 
University Hospital Leuven, Belgium.  
3.1 SUBJECTS 
The Malnutrition, Inflammation and Atherosclerosis (MIA) cohort is a patient cohort 
consisting of incident patients with CKD G5 (GFR<15 ml/min) sampled close to the start of 
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KRT at the Department of Renal Medicine, Karolinska University Hospital, Stockholm, 
Sweden. Patients are further followed up till death or transplantation. Patients were invited to 
attend additional visits after one year and two years on dialysis. This ongoing prospective 
cohort study started in 1994, and a descriptive protocol has been reported previously [81]. The 
study exclusion criteria were: age below 18 years, clinical signs of acute infection, active 
vasculitis or liver disease at the time of recruitment, or unwillingness to participate in the study. 
In the MIA study, patients have a median age of 56 years at inclusion, 63% are male, 36% have 
CVD and 30% have diabetes. Causes of CKD were chronic glomerulonephritis in about 22% 
of patients, diabetic nephropathy in about 26% of patients, autosomal dominant polycystic 
kidney disease (ADPKD) in about 12% patients and other or unknown etiologies in about 40% 
of patients. The vast majority of patients started dialysis therapy (either HD or PD) shortly after 
enrollment. Most patients were prescribed with commonly used drugs in CKD, e.g., phosphate-
and potassium-binders, diuretics, erythropoiesis-stimulating agents, iron substitution and 
vitamin B, C and D supplementation. In addition, 97% of patients received antihypertensive 
treatment (62% were prescribed with angiotensin-converting enzyme inhibitors and/or 
angiotensin II receptor antagonists (ACEi/ARB), 64% with beta blockers and 52% with 
calcium-channel blockers) and 28% of the patients used statins. The Swedish Ethical Review 
Authority approved the study (Dnr 2016/1470-31/4). This cohort constitutes the patient 
materials included in Studies I, II and V. 
The Mapping of Inflammatory Markers in Chronic Kidney Disease 2 (MIMICK2) is a 
cohort consisting of prevalent patients undergoing PD at Karolinska University Hospital at 
Huddinge and Danderyds Hospital, Stockholm, Sweden. This study originally aimed at 
investigating the variability of inflammatory parameters in prevalent PD patients over time. 
Recruitment of patients occurred from March 2008 through April 2011. The median age of 
patients is 64 years, 68% are males, 29% have CVD and 24% have diabetes. Causes of CKD 
were chronic glomerulonephritis in about 14% of patients, diabetic nephropathy in about 12% 
of patients, polycystic kidney disease in about 6% patients and other, or unknown etiologies in 
about 68% of patients. The Swedish Ethical Review Authority approved the study (Dnr. 
2007/1663-31) 
The Kärltx cohort is a prospective study cohort consisting of living donor kidney transplant 
(LD-RTx) recipients. Since March 2009, CKD patients undergoing LD-RTx at the Department 
of Transplantation Surgery of the Karolinska University Hospital are invited to participate in 
this study, which is designed to deepen the knowledge on inflammatory markers and proteins 
that affect bone turnover and vascular calcification in CKD patients. Blood and urine are 
collected prior to the transplantation procedure as well as at follow-up after 12 and 24 months. 
Artery biopsies and biopsies from fat and muscle are obtained from patients during the 
transplant surgery. Samples are utilized for a wide range of analyses, including assessment of 
biomarkers of inflammation, metabolism and atherosclerosis, as well as tissue staining and 
DNA and RNA assays. In addition, the vascular tissue undergoes histopathological 
examination to assess the degree of media calcification. As of the investigations reported in the 
thesis, a total of 199 patients were recruited. Their median age is 46 years, 69% are males, 15% 
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have CVD and 9% have diabetes. Causes of CKD were chronic glomerulonephritis in about 
33% of patients, diabetic nephropathy in about 6% of patients, ADPKD in about 10% of 
patients and other or unknown etiologies in about 51% of patients. The most commonly used 
medications before RTx were erythropoiesis-stimulating agents (82%), phosphate binders 
(90%), antihypertensive medications (55% with ACEi/ARB, 58% with betablockers and 55% 
with calcium-channel blockers) and statin use (35%). About 55% of the patients received 
dialysis treatment for a median period of 1.1 years before undergoing LD-RTx; 24% of the 
patients received PD, 28% received HD and 3% had both PD and HD, as two patients switched 
from PD to HD and three patients switched from HD to PD treatment. The Swedish Ethical 
Review Authority approved the study (no. 2008/1748-31/2, 2016/1790-32). 
The Leuven cohort is a prospective observational study comprised of CKD G5 patients 
referred for single kidney transplant at the University Hospital Leuven. The aim of this study 
is to investigate the natural history of bone histomorphometry and vascular calcification in 
dialysis-dependent patients before and after kidney transplantation. Adult patients (>18 years) 
eligible for kidney transplantation at the University Hospital Leuven are invited to participate 
in a kidney allograft protocol biopsy program. Exclusion criteria are: use of bisphosphonates 
within 6 months before the study entry, clinical signs of acute infection and unwillingness to 
participate in the study. Blood samples and bone biopsies (prior to kidney transplantation) and 
epigastric inferior artery biopsies (during kidney transplantation procedure) are collected and 
stored for a range of analyses. The ethical committees of University Hospitals Leuven approved 
the study (S52091). 
3.2 CLINICAL AND PHYSICAL EXAMINATION  
Each patient’s medical chart was reviewed and relevant data including underlying kidney 
disease, history of CVD, diabetes, other comorbid conditions, common medications, and 
survival were extracted.  
CVD was defined by clinical history of signs of ischemic cardiac disease, and/or presence of 
peripheral vascular disease and/or cerebrovascular disease. Smoking habits were recorded as 
current smokers, former smokers, and non-smokers. In the present studies, patients with current 
smoking habits are defined as smokers. The estimated glomerular filtration rate (eGFR) in the 
MIA and Kärltx cohort was estimated by the Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) formula [82]. In MIMICK2 cohort, total time on PD was defined as 
vintage time.  
FRS, an estimate of 10-year risk of developing CVD, was calculated from sex- and age- 
stratified formulas with scores for systolic blood pressure, diabetes, anti-hypertensive 
medication, total cholesterol, high-density lipoprotein (HDL) cholesterol and smoking status 
[83]. 
Survival was determined from the day of examination and sample collection, with no loss to 
follow-up of any patients. Cardiovascular death was identified by physicians and was defined 
as a result of sudden death, coronary heart disease, stroke or complicated peripheral vascular 
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disease. Causes of death were registered by a nephrologist blind to patient data and to the study 
objectives. 
Nutritional status  
Nutritional status was assessed using the subjective global assessment (SGA), with a four point 
scale grading system consisting of six components: three subjective assessments answered by 
the patients concern the patient’s history of weight loss, incidence of anorexia and vomiting, 
and three assessments performed by evaluators based on the subjective grading of muscle 
wasting, presence of edema and loss of subcutaneous fat [84]. On the basis of these 
assessments, each patient received a nutritional status score, 1 = normal nutritional status, 2 = 
mild malnutrition, 3 = moderate malnutrition and 4 = severe malnutrition. For the purpose of 
the study, poor nutritional status was defined as SGA score >1 and normal nutritional status 
was defined as SGA score = 1.  
Anthropometric evaluation 
At time of recruitment, body weight, body mass index (BMI, kg/m2), and other anthropometric 
measurements were obtained. Lean body mass and fat mass were calculated by anthropometry 
with measurements of biceps, triceps, sub-scapular and supra-iliac skinfold thickness using the 
Durnin and Womersley caliper method [85], and by equations proposed by Siri [86]. Lean body 
mass index and fat body mass index were calculated according to the method of Kyle et al [87] 
and expressed as kg/m2. Handgrip strength (HGS) was measured both in the dominant hand or 
in the hand without fistula (in the prevalent HD patients) using a Harpenden Handgrip 
Dynamometer (Yamar, Jackson, MI, USA). Each measurement was repeated three times for 
the measured hand, and the highest value was noted. For the analyses in the thesis, HGS was 
converted into percentage of sex-matched healthy subjects (% HGS).  
Augmentation index 
Assessment of arterial stiffness was performed non-invasively by SphygmoCorVR System 
(AtCor Medical, Sydney, Australia), using tonometry-based and cuff-based SphygmoCor 
Devices. The peripheral pulse waveform (PPW) was recorded from the radial artery at the wrist 
in non-fistula arm using applanation tonometry with a sensor probe. PPW and brachial blood 
pressure measurements were used to estimate central aortic pressure waveform calculated by 
the transfer function. Using the cuff-based SphygmoCor Device, brachial artery compression 
waveforms were obtained by partially inflating a cuff over the brachial artery between shoulder 
and elbow joint. Brachial waveforms were calibrated using cuff-measured brachial systolic and 
diastolic blood pressures, and then used to generate central aortic pressure waveforms by 
transfer function. Augmentation pressure (AP) and augmentation index (AIx) were derived 
based on pulse wave analysis. The merging of incident and the reflected wave (the inflection 
point) were identified on the generated central aortic pressure waveform. AP was defined as 
maximum systolic pressure minus pressure at the inflection point. AIx was defined as AP 
divided by pulse pressure and expressed as a percentage. In addition, because AIx is influenced 
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by heart rate, an index normalized for heart rate of 75 beats per minute (bpm) was used. 
SphygmoCor adjusts the AIx at an inverse rate of 4.8% for each 10 bpm increment. 
Skin autofluorescence  
Advanced glycation end-products autofluorescence was measured using an Autofluorescence 
AGE reader (DiagnOptics Technologies BV, Groningen, The Netherlands). Patients with 
tattooed and dark skin were not investigated. The AGE reader illuminates a skin surface of 1 
cm2, guarded against surrounding light, with an excitation light source between 300 and 420 
nm. Emission light (fluorescence in the wavelength range between 420 and 600nm) and 
reflected excitation light (with a wavelength between 300 and 420nm) from the skin are 
measured with a spectrometer. SAF was calculated as the ratio between the emission light and 
reflected excitation light, multiplied by 100, and expressed in arbitrary units (AU). All 
measurements were performed at room temperature in a semi-dark environment.  
3.3 BIOCHEMICAL MEASUREMENTS   
Blood samples were collected after an overnight fast or before dialysis session in HD patients 
after the longest interdialytic period. Plasma was separated within 30 min and was kept frozen 
at -70 °C if not analyzed immediately. Determinations of creatinine, albumin (bromcresol 
purple), calcium, phosphate, intact parathyroid hormone (iPTH), total cholesterol, low-density 
lipoprotein (LDL) and HDL cholesterol, triglyceride, hemoglobin, and high-sensitivity C-
reactive protein (hsCRP, high-sensitivity nephelometry assay) were measured by routine 
methods at the Division of Clinical Chemistry, Department of Laboratory Medicine, 
Karolinska University Hospital, Huddinge. The rest of biochemical parameters were mostly 
performed at Renal Lab of Division of Renal Medicine, Karolinska Institutet, or elsewhere in 
designated labs. Plasma interleukin-6 was analyzed by immunometric assays on an Immulite 
1000 Analyzer (Siemens Healthcare Diagnostics, Los Angeles, CA, USA) using commercial 
kits (coefficient of variation, CV 4%). Total osteocalcin (N-MID; Immunodiagnostic Systems, 
Boldon, UK) and inactive/active carboxylated osteocalcin (Takara Bio, Otsu, Shiga, Japan) 
were analyzed with Commercial ELISA Kits. Klotho was measured by Human solubleα-
Klotho ELISA Assay from IBL International (Hamburg, Germany) and human FGF23 (C 
terminal) was measured by ELISA Kit from Immutopics International (San Clemente, CA). 
Total alkaline phosphatase (ALP) activity was measured with Commercial Reagent Kit 
(Alkaline Phosphatase (IFCC) Plus; Thermo Fisher Scientific Oy, Vantaa, Finland) by an 
automatic chemical analyzer (Konelab 20XTi; Thermo Electron Corporation, Vantaa, Finland) 
and bone ALP (BALP) was measured using Ostase BAP ELISA kit (Immunodiagnostic 
Systems, Boldon, UK).  
Vitamin K status was indirectly evaluated by measuring plasma dp-ucMGP levels in a single 
run by the Laboratory of Coagulation Profile (Maastricht, the Netherlands) using the 
commercially available IVD CE-marked chemiluminescent InaKtif MGP assay on the IDS-
iSYS system (Immunodiagnostic Systems, Boldon, UK) [88]. In brief, plasma samples and 
internal calibrators were incubated with magnetic particles coated with murine monoclonal 
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antibodies against dp-MGP, acridinium-labelled murine monoclonal antibodies against 
ucMGP and an assay buffer. The magnetic particles were captured using a magnet and washed 
to remove any unbound analyte. Trigger reagents were added, and the resulting light emitted 
by the acridinium label was directly proportional to the level of dp-ucMGP in the sample. The 
analytical range was between 300 and 12,000 pmol/L and was linear up to 11,651 pmol/L. The 
within-run and total variations of this assay were 0.8–6.2% and 3.0–8.2%, respectively.  
Serum levels of indoxyl sulfate (IndS), p-Cresyl sulfate (pCS), trimethylamine N-oxide 
(TMAO), phenylacetylglutamine (PAG) were quantified using a dedicated ultra-performance 
liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method as described 
elsewhere [89]. 
3.4 CORONARY ARTERY CALCIUM AND AORTIC VALVE CALCIUM  
Coronary artery calcium (CAC) and aortic valve calcium (AVC) were measured by 64-channel 
detector scanner (LightSpeed VCT; General Electric (GE) Healthcare, Milwaukee, WI, USA) 
in cine mode. Scans were ECG-gated and a standard non-contrast media protocol was applied 
using a tube voltage 100 kV, tube current 200 mA, rotation time 350 ms, slice thickness 2.5 
mm and a display field of view of 25 cm. CAC data were processed and analyzed using an 
Advantage Workstation (GE Healthcare, Milwaukee, Wisconsin, USA). CAC was assessed as 
a lesion with an area > 1 mm2 and a peak intensity >130 Hounsfield Units (HU) based on the 
Agatston method and expressed in Agatston units (AU) [9]. The Agatston score is calculated 
using a weighted measurement to the highest density of calcification in a coronary artery. The 
density is expressed in Hounsfield units, and graded as 1 = (130-199 HU), 2 = (200-299 HU), 
3 = (300-399 HU), and 4 = (400 HU). The Agatston score is a product of density and area 
(mm2) of coronary calcification. The Agatston score of each plaque is then summed for all 
image slices of the heart (left main artery, the left anterior descending artery, the left circumflex 
artery and the right coronary artery) to determine the total CAC score. The total volume score 
(CAC volume, mm3) is a product of total area score (CAC area) and slice thickness 
(2.5mm)[13]. AVC-scores were computed using the Agatston CAC-scoring method from non-
contrast cardiac CT scans. AVC was defined as the sum of calcium in aortic valve area 
including calcium within valve leaflets as well in aortic wall immediately connected to the 
leaflets. Presence of AVC and CAC was defined as total AVC score>0 and CAC score>0, 
respectively. 
3.5 ARTERY BIOPSIES AND MEDIA CALCIFICATION SCORING  
Within 20 min after skin incision at start of surgery, one piece (1-2 cm in length) of the inferior 
epigastric artery was collected by sharp dissection. Samples were immediately placed in 
AllProtect Tissue Reagent (Qiagen, Hilden, Germany) or snap frozen and subsequently stored 
at −70 °C, or fixed in 4% phosphate-buffered formalin. Formalin-fixed tissues were embedded 
in paraffin. One- to two-µm-thick sections were stained with hematoxylin and eosin and von 
Kossa staining, respectively. The degree of media calcification was semi-quantified on von 
Kossa-stained sections and graded 0 to 3 by an experienced pathologist: score 0 indicates no 
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calcification, score 1 indicates minimal calcification, score 2 indicates moderate calcification 
and score 3 indicates extensive calcification. In Study III, patients with score 0 (n=25) and 1 
(n=68) were combined into one group representing no-minimal media VC (n=93), while those 
having moderate (score 2; n=38) or extensive (score 3; n =21) signs of VC were combined into 
another group representing moderate-extensive media VC (n = 59).  
3.6 STATISTICAL ANALYSES 
Data are expressed as median (either 10th-90th percentile or 25th-75th percentile interquartile 
range (IQR)), mean (standard deviation, SD), number, or percentage, as appropriate. Statistical 
significance was set at the level of p <0.05. Comparisons between two groups were assessed 
with the non-parametric Wilcoxon test for skewed continuous variables and t test for normally 
distributed continuous variables and Fischer´s exact test for nominal variables. Comparisons 
between more than two groups were assessed with Kruskal-Wallis test for the non-parametric 
continuous variables, one-way analysis of variance (ANOVA) for normally distributed 
variables and Chi-square test for nominal variables. Spearman rank correlation analysis was 
used to determine associations between two variables. Multivariate associations were 
performed by multiple linear regressions and multinomial logistic regression analyses.  
In Study III, the relaxed linear separability (RLS) method was applied to select the subset of 
features associated with VC. The term “relaxed” in the name of the method means the 
deterioration of the linear separability (between two groups of patients) due to the gradual 
neglecting of selected features. Initially, in the RLS algorithm, the optimal hyperplane that 
separates patients from two groups, is determined. This hyperplane is usually described by a 
large number of features. The repeated minimization of criterion function with a gradual 
increase of regularization parameter of RLS method allows to generate in a deterministic 
manner the descending sequence of feature subsets. In the process of evaluation of each feature 
subset, the cross-validation (leave one out) procedure was used. The apparent error (AE) and 
the cross-validation error (CVE) determined the errors on the training and testing parts of the 
data, respectively, and both denote the proportion of misclassified patients. The feature subset 
with minimal CVE was selected as optimal and applied on data of all patients to determine 
receiver operating characteristic (ROC) curve and check classification accuracy. The details of 
RLS feature selection method were presented elsewhere [90,91]. Missing values were assigned 
using k-nearest neighbor algorithm at k = 1 using “knnimpute” function from Bioinformatics 
Toolbox (Matlab 2018b, Mathworks, Natick, MA, USA). In total 8% of missing values were 
imputed. The mean values of features in the resultant dataset differed on average by 1.21 ± 
1.73% from the original data; however, for none of the features the difference was statistically 
significant.. The imputation of missing values did not involve the outcome variable. The RLS 
model was applied for the final dataset with complete set of values, whereas all the other 
methods operated on the original data set. 
Survival analyses were conducted with Fine & Gray competing-risk regression models with 
kidney transplantation as a competing risk to establish cumulative incidence curves. The 
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relative risk for mortality was presented as sub-hazard ratio (sHR, 95% confidence interval 
(CI)). 
Statistical analyses were performed using statistical software SAS version 9.4 (SAS Campus 
Drive, Cary, NC, USA), Stata 16.1 (Stata Corporation, College Station, TX, USA) and Matlab 
(2018b, Mathworks, Natick, MA, USA). Figures were created using GraphPad Prism (version 
9.0 GraphPad Software, www.graphpad.com). 
3.7 STUDY CONSIDERATIONS 
Strengths of the studies 
The access to relatively large and extensively phenotyped cohorts of CKD patients followed 
for several years - and with no patients lost during follow-up - that allowed analyses of long-
term consequences of VC with many potential confounders being taken into account represents 
a major strength of our studies. While the observational nature of the investigations does not 
allow us to draw conclusions on causality, our studies yielded several novel observations 
representing in some cases the first reported associations in this research field that we hope will 
stimulate and guide future research activities aiming at elucidating disease etiology, diagnosis, 
prognosis and adverse effects of VC in CKD.  
Limitations of the studies 
a) study design  
First, the studies presented in this thesis are of post hoc nature and therefore do not allow 
conclusions regarding causality. Secondly, during the long recruitment time window of the 
Kärltx (ongoing since 2009) and MIA (patients recruited between 1994-2014) cohorts, updated 
clinical guidelines with recommendations for therapeutic changes were introduced affecting 
the treatment of the patients. For example, use of non-calcium phosphate binders and statin 
therapy increased during recent decades. Thirdly, all investigated patients represent a selected 
group of those individuals surviving earlier stages of CKD and with no complications 
excluding them from participation. Among investigated patients, those from Kärltx and Leuven 
cohorts represent individuals eligible to undergo kidney transplantation that are younger and 
healthier than average incident patients receiving KRT in Sweden. This selection bias thus 
limits the generalizability of our results to the whole CKD population. On the other hand, it is 
a strength that investigated patients are not burdened by very high age and acute complications 
as these factors could have overshadowed the impact of typical pathways leading to VC.   
b) clinical measurements 
Many, if not all clinical assessments, are at least to some extent not objective. Data on diagnosis 
were obtained from medical charts, which provided diagnoses that not necessarily had been 
confirmed by detailed clinical investigations and also did not separate between different 
degrees of severity. For instance, a patient who had a history of aortic aneurysm, could have 
had one or several incidences of myocardial infarction, angina pectoris, cerebrovascular lesion 
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or peripheral arterial insufficiency; all were diagnosed as CVD. Clearly, this general grouping 
may fail to cover the severity of underlying etiologies of CVD that would influence the course 
and prognosis of the disease. Also, as we relied on medical charts, we cannot exclude that some 
previous events taking place at other hospitals were not appropriately recorded or overlooked; 
therefore, mostly likely, the overall presence of CVD may be underestimated in our patient 
materials. Also, causes of death are collected from the medical records and death certificates. 
Autopsy that may be required to establish the actual cause of death is usually not performed. 
Hence, the cause of death represents an opinion of the physician issuing the death certificate 
and for other reasons noted above the use of “cardiovascular mortality” as an endpoint of 
clinical investigations is likely to be biased. Thus, in some studies presented in this thesis, in 
which we test “cardiovascular mortality” as sensitivity analysis, we prefer using overall deaths,  
i.e., all-cause mortality as this unquestionably represents the most robust definition of the 
ultimate clinical endpoint.  
SGA is by design subjective and thus subject to bias as it relies on subjective assessments 
including patients’ self-reported answers to patient-related outcomes. Also, while the SGA 
assessment was conducted by trained nurses, we cannot rule out intra- and inter-individual 
variations [92]. Even so, we and others have reported that SGA is a strong predictor of clinical 
outcomes in CKD patients[93–95], suggesting that SGA provides a meaningful measurement 
of nutritional status. In Study II, aside from AVC, SGA also shows a strong association with 
mortality with multiple adjustments. In addition, anthropometric measurements, e.g., skinfold 
thickness and body weight (and BMI calculation), may be influenced by fluid retention and 
hydration status and shall be interpreted with caution in the setting of CKD.  
c) biochemical measurements 
Some of the biochemical measurements presented in this thesis have been measured post hoc 
from frozen samples. Thus, we cannot rule out the possibility of sample degradation due to 
long-term storage or sample alterations due to repeated thawing and refreezing processes. Also, 
it shall be noted that biochemical measurements in these studies are based on one single time 
point whereas the investigated molecules may vary over time influenced by various factors and 
conditions.  
d) statistical methods 
Due to the observational design of the studies and insufficient sample size, and, despite 
extensive phenotyping, we are not able to control for all possible confounders in these 
investigations, while, in some cases, we may have induced over-adjustment. However, we have 
attempted to remove factors in regression models suspected to have collinearity and to avoid 
adjusting for factors that are pathophysiologically related. Also, as some may hold against 
dichotomizing continuous variables in multiple regressions, we have sometimes done so given 
that a limited sample size did not allow determining associations per units of increase. In 
addition, though sex differences may be reflected in the course of age-related diseases, we did 
not perform sex-stratified statistical analyses mainly due to a limited sample size.  
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4 MAIN RESULTS AND DISCUSSIONS 
4.1 CAC COMPONENTS AND AVC IN RISK PREDICTION 
The studies presented in the thesis (Study I and II) further demonstrated the prognostic value 
of cardiac atherosclerosis, with a focus on coronary atherosclerosis (represented by CAC score 
and its components, i.e., CAC density and volume) and aortic valve calcium (AVC), in risk 
prediction in the context of uremic milieu.  
The Agatston CAC score adds to FRS for CVD prediction and improves risk stratification in 
various study populations [10]. While higher CAC volume associates with worse outcomes in 
the general population [14,96–99], it has been proposed that increased CAC density in the 
arterial wall reflects plaque stabilization[100–103], leading to reduced risk of coronary events 
[104]. However, recent reports suggested that the density of calcium in the plaques was not 
associated with mortality in patients with type 2 diabetes[15] and a high density of calcified 
plaques was independently associated with increased all-cause mortality in HD patients [14]. 
Thus, in these complex disease scenarios, the role of CAC density in risk prediction and plaque 
stabilization is yet to be determined. In Study I, we reported an inverse J-shaped relationship 
between CAC density and mortality in advanced CKD G5 patients, with middle tertile of CAC 
density being associated with the highest mortality and highest tertile of CAC density forming 
an intermediate risk group (Figure 1). It is plausible that with the concurrence of traditional 
risk factors with uremia-related risk factors, such as hyperphosphatemia, hypercalcemia, 
hypomagnesemia, hyperparathyroidism together with a diminished effectiveness of factors 
within the VC inhibitory system (e.g., fetuin-A, MGP, osteoprotegerin (OPG)), CKD patients 
are predisposed to a more complex conundrum of vascular aging processes over and above 
single entities promoting VC. Our data indicate that high CAC volume associates with 
inflammation, malnutrition and low handgrip strength. The concurrent inflammation, 
sarcopenia and atherosclerotic calcification burden may reflect such a progressive aging 
process in CKD. Moreover, we observed that inflammation modifies the relationship between 
CAC density and mortality, supporting the catalytic effect of inflammation on cardiovascular 













Figure 1. Crude mortality rate/1000 patient-years (95% CI) according 
to tertiles of (A) CAC score, (B) CAC volume and (C) CAC density 
(n=207) and in patients with a CAC score of 0 (n=89). Figure from 




Both intima and media calcification can be co-existent in CKD [4]. In Study I, we report that 
the extent of arterial media calcification in epigastric arteries was significantly associated with 
both high CAC volume and high CAC density. Interestingly, while medial layer appears to be 
the major histological sites affected by calcification in epigastric arterial biopsies, 14% of 
patients with extensive media calcification were absent from coronary calcification. Hence, the 
magnitude and susceptibility for calcification can differ between divergent arterial sites [107]. 
Though CT scanning yielding CAC score does not differentiate between intima and media 
calcification, it is likely that CAC to a larger extent represents calcium in the intimal layer of 
coronary arteries which are more susceptible to atherosclerotic calcification. Since both intima 
and media calcification are associated with poor clinical outcomes, focusing on CAC density 
in single anatomical arteries trees (i.e., coronary arteries) may fail to represent overall 
calcification burden and its implications for risk prediction in CKD. Another complicating 
factor is that as conventional CT scanning cannot identify the calcified plaque pattern 
(microcalcification and macrocalcification), and thus it is a challenge to determine whether a 
high calcium density score or the aggravation of calcium score truly represents the underlying 
stabilization of calcified plaques. 
In Study II, we further explore the prognostic value of AVC and report that the presence of 
AVC is associated with all-cause mortality, independent of coronary calcification indicated by 
CAC score, inflammation, malnutrition, and FRS in CKD G5 patients (Figure 2). Aortic valve 
calcification, another hallmark of premature vascular aging, is prevalent among 25% of 
individuals >65 years [108] and can progress into aortic valve stenosis causing left ventricular 
obstruction. Data from the Multi-Ethnic Study of Atherosclerosis (MESA) study found a 13% 
prevalence of AVC and 11% of overlap prevalence of AVC and CAC in the general population  
[109]. Moreover, adjusting for the presence of subclinical atherosclerosis (estimated by CAC 
score) and inflammation, the presence of AVC was independently associated with increased 
risks of coronary and cardiovascular events, suggesting a prognostic value of AVC in risk 
prediction beyond that of coronary atherosclerosis [109]. In dialysis patients, cardiac valve 
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calcification is 4-5 times more prevalent compared to the general population [110–113]. 
Similar to atherosclerosis, pathological factors involved in valve calcification include 
traditional risk factors, inflammation and disordered bio-mineralization [114]. Here, our study 
shows that AVC was present in 39% of the investigated CKD G5 patients and that overlapping 
presence of AVC and CAC was 37%, which is >3 times higher than that reported in the general 
population (11%)  [109] (Figure 3). More importantly, as observed in the general population, 
our data support the strong prognostic role of AVC in risk prediction, which is beyond 
subclinical coronary atherosclerosis (CAC>0), traditional risk factors, inflammation, and  
nutritional status in advanced CKD. 
  
 
Figure 2. AVC associates with all-cause mortality 
independent of CAC, inflammation and other factors 





Figure 3. Prevalence of four groups of patients 
according to presence (+) or not (-) of aortic valve 
calcium (AVC) or coronary artery calcium (CAC). 
Figure from Study II [115]. 
 
                                           
 
Premature vascular aging (e.g. atherosclerotic VC, media VC and EVA) is highly prevalent in 
CKD [2,116,117] and calcification can take place with different histological and anatomical 
forms. This is further supported in our sub-analyses whereby 86% of patients were found to 
have calcification either in coronary arteries estimated by CAC, aortic valves estimated by 
AVC or/and media calcification in epigastric arteries estimated by histological scoring (Figure 
4A). Whereas an overall similar trend of progression of AVC and CAC was observed in 
response to the severity of media VC, the proportions of AVC and CAC in different media VC 
groups differed remarkably (Figure 4B-D), suggesting that distinct mechanisms of 


































0 2 4 6




















Figure 4. Prevalence of calcification at three sites, inferior epigastric artery, aortic valve (AVC) and coronary 
artery (CAC) among 102 CKD G5 patients who underwent both arterial biopsies and cardiac CT imaging. (A) 
Presence of calcification detected at three vascular sites. (B) Prevalence of AVC with severity of media VC. (C) 
Prevalence of CAC with severity of media VC. (D) Prevalence of combined presence of CAC and AVC with 
severity of media VC. Figure from Study II [115]. 
Given the cross-sectional nature of the study design, the true relation between CAC density 
and mortality may not be accurately reflected and the “inverse J-shaped” pattern observed in 
Study I further reflects a complex scenario of VC in the setting of CKD. Also, the strong 
predictive value of AVC for mortality suggests that AVC should be considered and included 
in the standard risk evaluation in advanced CKD. Long-term prospective studies are warranted 
to evaluate the joint impact of evolution of CAC components, AVC, concomitant media 
calcification and other potential risk factors on clinical outcome. 
4.2 PHENOTYPIC FEATURES OF MEDIA CALCIFICATION  
In Study III, we have identified 17 features including traditional risk factors and novel 
biomarkers associated with histologically verified media calcification in a clinical dataset of 
CKD G5 patients undergoing LD-RTx. The identification of risk factors promoting media 
calcification in patients with a complex disease condition (e.g. CKD), is challenging as it 
requires handling of a multifactorial panel of factors involved in VC. Here we applied 
multifactorial RLS model by taking all available factors into account concomitantly to 
minimize the risk of statistical errors as this may provide a biologically more relevant way of 
analyzing data. In contrast to traditional models, where factors are tested one by one or in pre-
selected groups versus an outcome, the RLS method provides a holistic and less biased 
selection of risk factors that concomitantly associate with presence of VC in the uremic milieu. 
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Among 62 features, a feature set of 17 factors was obtained representing the best feature panel 
with the lowest CVE (0.16), which allows 89% of the subjects to be correctly classified to their 
respective groups (Figure 5). We identified that media calcification is largely associated with 
traditional risk factors, bone turnover markers, as well as with several novel biomarkers (Table 
2). Also, by comparing performance of RLS with traditional logistic regression model, we 
found that four parameters identified as determinants of VC in the multivariate logistic 
regression model, i.e., age, sex, BMI and OPG, were also present among the 17 features 
identified by the RLS. Nevertheless, the predictive performance using logistic regression was 
lower than that achieved by RLS with 76% vs. 89% of subjects, respectively, correctly 
classified into their groups. In accordance, the ratio of true-positive to false-positive rate was 
less advantageous in logistic regression than in RLS model with the area under ROC curves 
being 0.80 in logistic regression and 0.91 in RLS selection (Figure 6).  
 
 
Figure 5. Cross-validation error (CVE) and apparent 
error (AE) during RLS procedure. RLS model was 
applied to separate patients with vascular calcification 
from non-calcified patients among 152 CKD G5 
patients. A total of 63 features (including media 
vascular calcification score) were entered into the 
model. The lowest possible CVE was achieved with 







Figure 6. Receiver operating characteristic (ROC) 
curves with area under curve (AUC) for relaxed 
linear separability (RLS), red dotted curve, and 
multivariate logistic regression methods, blue 









































Table 2. List of 17 features derived from RLS method as predictors of media calcification in 152 
CKD G5 patients. Table modified from Study III [118]. 
No. Feature Name RLS factor No. Feature Name RLS factor 
1 sRANKL 4.05 10 fT3 -1.58 
2 Diabetes  3.67 11 TRAP 5a -1.51 
3 Age 3.55 12 MOTSc 1.48 
4 Angiopoietin 2 3.22 13 CTX 1.41 
5 Cholesterol 3.15 14 IgM antiMDA 1.40 
6 BMI  2.95 15 OPG 1.30 
7 Sex, Male vs Female 2.54 16 iPTH 1.26 
8 Uric acid 2.48 17 Betaine -0.95 
9 IgM antiPC -1.82    
 
It shall be, however, acknowledged that this model is based on a data set of CKD patients 
undergoing LD-RTx who had specific clinical characteristics and phenotypic measurements 
unique to this cohort. Therefore, pre-selection of features was largely based on already 
available knowledge about potentially relevant factors of VC; vice versa, unmeasured markers 
proven to be related to media calcification were not included in the analysis. Also, as we 
discussed in the previous studies about the existence of various forms of VC in CKD, 
calcification in one single vasculature bed may not be sufficiently representative for the entire 
vascular system. Nevertheless, this study represents a novel approach that may have the 
capacity to identify unknown combined effects of individual phenotypic features. While the 
validation of phenotypic features associated with biopsy-verified vascular media calcification 
needs replication in other cohorts, our findings, if confirmed, may facilitate future 
investigations on EVA without the need of taking arterial biopsies. 
4.3 SEVELAMER USE AND GUT MICROBIAL METABOLISM 
With recent increased awareness of drug-microbiome interactions [51], in Study IV, we 
explored the possible link between sevelamer therapy and markers of gut microbial metabolism 
and show that sevelamer use is associated with increased exposure to gut-derived uremic toxins  
represented by circulating concentrations of IndS and PAG, and a poor vitamin K status, in 
CKD G5 patients. In CKD, the high prevalence of vitamin K insufficiency is mainly attributed 
to dietary restrictions [119] and impaired vitamin K recycling [120]. Multiple lines of evidence 
suggests that poor vitamin K status is involved in the pathogenesis of VC and bone fragility, 
both of which are common uremic features [121–123]. Here we found that patients treated with 
sevelamer had a poor vitamin K status, confirming and extending a recent finding from a 
smaller cohort study [46]. It is likely that sevelamer sequesters vitamin K through the 
gastrointestinal tract and abates its absorption. However, in vitro studies evaluating the binding 
of sevelamer and vitamin K (both phylloquinone and menaquinone) yielded conflicting results 
[47,124] and answers remains to be addressed as whether sevelamer interferes with vitamin K 
bioavailability. Intriguingly, we found an independent association between low vitamin K 
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status and high serum levels of PAG and TMAO. Though our observational study design 
precludes solid conclusions on the causality, this may suggest a possible link between gut 
dysbiosis and vitamin K deficiency. It is plausible that while gut dysbiosis may lead to 
decreased endogenous microbial synthesis of vitamin K, a low availability of vitamin K in the 
gut, may alternatively disrupt gut microbial metabolism (Figure 7). Indeed, it has been 
indicated that menaquinones are necessary growth factors to modulate human gut microbiome 




Figure 7. Sevelamer use and 
microbial metabolism in end-stage 





In addition, we observed that sevelamer treatment was associated with high IndS and PAG, 
independent of traditional and non-traditional factors such as age, sex, phosphate, creatinine 
and dialysis vintage. While this finding seems to be contradicted by some in vitro studies 
showing chelation of the precursor compounds by sevelamer [127,128], it is supported by a 
study [129] reporting that 8-week sevelamer hydrochloride treatment in HD patients did not 
alter serum IndS and Indole-3-acetic acid (IAA), but increase serum pCS. It can be speculated 
that sevelamer may alter the gut microenvironment, either by dragging nutrients and minerals 
into the colon and/or prolonging the colon transit time, and eventually result in accentuated 
protein fermentation (Figure 7). 
As such, our observations that sevelamer use is associated with vitamin K deficiency and 
increased exposure to uremic toxins may indicate clinical trade-offs of sevelamer therapy and 
moreover, explain some of the neutral or negative findings in intervention studies [130,131]. 
The fact that pharmaceutical drugs have both beneficial and unfavorable effects is not restricted 
to sevelamer. A recent survey revealed that 24% of drugs may have an impact on the gut 
microbiome suggesting that a better understanding of  drug-bug interactions can facilitate side 
effect control beyond the benefits [51]. Much research work remains to be performed in this 
area to illustrate such effects, including mechanistic and prospective studies to address possible 
causal links between sevelamer use and disturbed gut microbial metabolism. Also, our findings 
need to be testified in cohort studies with considerable information on diet and residual kidney 
function which are missing in the current investigation.  
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4.4 VITAMIN K STATUS, VC AND MORTALITY 
In Study V, we investigated the clinical associations between functional vitamin K deficiency, 
VC, and all-cause mortality in advanced CKD. We observed an independent association 
between high dp-ucMGP and increased risk of all-cause mortality which is not modified by the 
presence of VC represented by CAC and AVC (Figure 8). Also, we found that dp-ucMGP is 
not an independent determinant of presence of CAC and AVC (Table 3). This comes as an 
unexpected finding but it shall be noted that whilst the role of MGP in VC is well established 
in animal models [53–55], data regarding the association between dp-ucMGP and VC remain 
inconclusive in the clinical setting. Whereas some observational studies showed a positive 
association between circulating dp-ucMGP and VC [65,72,74,132], others have failed to do so 
[71,75,133–135]. Corresponding to a post hoc analysis of a randomized trial showing that dp-
ucMGP was not associated with baseline CAC, nor that the change of dp-ucMGP was 
associated with the change in CAC after 3-year vitamin K supplementation, our data also did 
not support dp-ucMGP as an independent determinant of CAC and AVC. One possible 
explanation can be the intrinsic contrast between high dp-ucMGP turn-over and slow 
progression of VC, making it difficult to observe a temporal association between dp-ucMGP 
and VC at one single observational time. Prospective studies investigating the dynamic changes 
of dp-ucMGP and VC development at multiple time windows may fulfill this gap in 
knowledge. In addition, as we have previously discussed that since cardiac CT scan of calcium 
score was determinant in differentiating macro- and micro-calcification, VC represented by 
CAC and AVC may underestimate the underlying microcalcification pattern. Therefore, the 
observed relation between dp-ucMGP and calcium score in our study and in most other current 
research work cannot mirror the true relation between dp-ucMGP and calcium score. Future 
studies investigating the role of dp-ucMGP in micro- and macrocalcification are in need as to 




Figure 8. Associations of dp-ucMGP with all-cause mortality in all 
patients (A, n=493) and sub-group of patients with assessment of CAC 
(B, n=237) and AVC (C, n=223). Model 1, adjusted for age, sex, 
cardiovascular disease, diabetes, body mass index, inflammation, and 
dialysis treatment; Model 2: model 1 plus presence of CAC; Model 3, 













































Table 3. Determinants of the presence of vascular calcification*. Table from Study V [136]. 
 
Presence of CAC 
(n = 237, pseudo r2 =0.45) 
Presence of AVC 
(n = 223, pseudo r2 =0.29) 
 OR 95% CI  OR 95% CI 
Age, per 1-SD increase  8.10 4.43-14.81  3.83 2.39-6.14 
Diabetes, yes/no 10.49 1.32-83.18  - - 
Beta-blocker, yes/no - -  2.23 1.03-4.78 
Albumin, per 1-SD increase - -  0.59 0.41-0.85 
* Multivariate logistic regression with stepwise backward selection of variables.  
 
In agreement with pioneering work suggesting functional vitamin K deficiency as a risk factor 
of mortality and cardiovascular events in a variety of study populations [62–69,137], our study 
showed that higher dp-ucMGP is independently associated with increased all-cause mortality 
risk, after adjustments for relevant confounders (e.g. age, sex, BMI, CVD, diabetes, 
inflammation and dialysis treatment). Moreover, this association withstood further adjustment 
for presence of VC, lending support to the speculation that functional vitamin K deficiency 
may affect clinical outcome in CKD via pathways beyond one single entity of VC. Indeed, 
vitamin K deficiency may be linked to the “diseasome of aging” [138]. A large amount of 
clinical evidence posits the involvement of vitamin K deficiency in non-cardiovascular age-
related diseases/complications including physical decline [139], frailty [78], osteoporosis 
[140], fractures [122,141] and depression [142]. Recently, a meta-analysis incorporating data 
from three large cohorts concluded that low circulating phylloquinone (reflecting dietary 
vitamin K intake) was associated with an increased risk of all-cause mortality, but not with 
CVD [143]. These results are in line with the findings in our study that circulating dp-ucMGP 
was not an independent determinant of VC, nor was the association between dp-ucMGP and 
all-cause mortality modified by the presence of VC. Nevertheless, our study is limited by the 
observational design and we are not able to explain this non-significant association between 
dp-ucMGP and VC with supportive evidence. Also, dp-ucMGP and VC were measured at one 
single time point (i.e. at baseline), and repeated measurements over time can be more reflective 
regarding the true interplay between dp-ucMGP and VC. However, this “non-positive” finding 
may motivate future research to explore more about the role of vitamin K deficiency in the 
pathophysiology of cardiovascular health, and more importantly, to illustrate its less explored 







5 CONCLUSIONS  
I. The relationship between CAC density and mortality is “inverse J-shaped” in CKD G5 
patients, with middle CAC density tertile being associated with the highest mortality and 
highest CAC density tertile forming an intermediate risk group. 
II. The overlap of AVC and CAC (37%) was three times higher in advanced CKD than that 
reported in the general population. AVC associated with increased mortality risk independent 
of presence of CAC, traditional risk factors and inflammation. 
III. The RLS model identified 17 features including traditional risk factors and novel 
biomarkers that each - when analyzed together - concomitantly associated with biopsy-verified 
media VC in advanced CKD.  
IV. Sevelamer use is associated with disturbed gut microbial metabolism as indicated by high 
serum IndS and PAG levels and a poor vitamin K status in CKD G5, suggesting a possible 
drug-bug interaction whereby sevelamer therapy could alter gut microbiome as a potential 
trade-off of improving phosphate control. 
V. Functional vitamin K deficiency is associated with increased mortality risk in CKD G5, 
independent of the presence of CAC and AVC. The results highlight the need for further studies 
illustrating the role of vitamin K deficiency in mediating cardiovascular and non-
















6 DIRECTIONS OF FUTURE RESEARCH 
In the present work, we performed observational studies to expand the knowledge of risk 
factors and prognostic value of VC in the context of CKD. We observed several novel and 
intriguing associations that, as a next step, may guide the design of longitudinal explorations, 
interventional and mechanistic studies, aiming at establishing causal relationships and possibly 
leading to improved diagnostic, preventive and therapeutic strategies for this severe 
complication of CKD. 
The current finding that the role of CAC density score in predicting clinical outcome in CKD 
is contradictive to the assumption of its role in the general population implies that more details 
of CAC scoring need to be delineated. Indeed, CAC density score provides only the average 
density of calcified lesions, not the density of each lesion; however, both low- and high-density 
calcified plaques can co-exist in the same patient. Explorations into the role of each individual 
lesion’s CAC density would provide new insights into the prognostic value of CAC scoring. 
Also, to further understand the predictive role of plaque density in clinical outcome, it would 
be interesting to evaluate the dynamic effects of micro- and macro calcification plaques in risk 
prediction. The use of 18F-sodium fluoride PET-CT imaging might be promising to detect 
microcalcification in vulnerable plaques; however, longitudinal follow-up studies evaluating 
the validity of 18F-sodium fluoride PET-CT imaging are needed to establish its value as 
diagnostic tool to identify microcalcification in CKD. While we found a strong prognostic 
value of AVC in risk prediction, it is important to note that the susceptibility of being calcified 
at vascular sites is not uniformly distributed in the vasculature. Although all vessels may have 
the potential to calcify, only a certain portion of vascular trees develop typical atherosclerosis, 
e.g. coronary arteries, aortic arteries/branches, and arteries of the abdomen and lower 
extremities. By contrast, others appear fairly or thoroughly resistant to the atherogenesis, such 
as the arteries of the upper extremities. Further studies are needed to unveil mechanisms 
underlying the susceptibility to calcification in vascular trees and, from a clinical perspective, 
it is important to compare or combine the prognostic value of calcification at different sites in 
CKD population.  
The RLS feature selection identified several less-explored novel risk factors of media 
calcification which may inform further investigations required to illustrate the underlying 
mechanisms that mediate the process of media VC in CKD. Also, the resulting feature set 
predicting media VC derived from this cohort needs to be further tested and validated in other 
CKD cohorts with similar phenotype pattern. Moreover, the clinical challenge to differentiate 
media calcification from intima calcification and to quantify media calcification non-invasively 
rather than by taking biopsies is to be tackled. The recent development of a nanoparticle-based 
test of the calcification propensity (T50) [144] may be of value as a clinical approach to 
evaluate the risk of VC in CKD; yet, the specificity and sensitivity is to be validated. Hopefully, 
the development of artificial intelligence and use of big data algorithms would help to provide 
advanced diagnostic models. 
 
28 
While we observed an association between sevelamer use and markers of disturbed microbial 
metabolism, the possible causal relationship between the two needs to be determined with 
longitudinal and interventional studies. Also, the direct role of sevelamer use as well as other 
common drugs (e.g. proton-pump inhibitors and iron supplementation) in gut microbial 
profiles/patterns is to be explored in vitro and in vivo. As such, a better knowledge of drug-bug 
interactions may provide solutions for side effect control. The observed association between 
vitamin K deficiency and increased risk of mortality, independent of CAC and AVC, requires 
further evidence-based explanations. Prospective studies with repeated measures over time 
would be more accurate in reflecting the long-term interplay between dp-ucMGP and VC. 
Also, as previously mentioned, the different susceptibility to calcification propensity and 
different patterns of micro- and macro-calcification in different vascular trees could potentially 
be incorporated in the construction of new measures of the actual presence and evolution of 
VC. Our observations on calcification, represented by CAC and AVC, may be biased measures 
underestimating the true presence and missing out the true identity of VC. Future studies 
incorporating anatomical (i.e. different vascular sites), histological (i.e. media and intima VC) 
and dynamic patterns of calcification (i.e. micro- and macro-calcification) with long-term 
follow up are warranted to address and tackle the potentially biased research findings. 
It is worth to note that while we normally focus on identifying risk factors as potential 
interventional targets to reduce disease progression, the protective mechanisms have not been 
equally investigated in cardio-metabolic research. A recent concept of the opposite extreme of 
EVA, i.e., supernormal vascular aging (SUPERNOVA) [145,146], may introduce a new 
perspective to explore protective mechanisms of EVA by studying subjects who exhibit an 
exceptional resistance to arterial stiffness for their age and sex. This concept can be further 
extended to investigate subjects with other extreme phenotypes with absent or minimal signs 
of vascular aging including premature atherosclerosis and media calcification. By contrasting 
extremes, it may be possible to discover novel biomarkers and preventative/therapeutic targets 












7 SOCIAL IMPACT  
In 2017, approximately 860 million people were estimated to have kidney disease, including 
CKD stage 1-5 (843.6 million), acute kidney injury (13.3 million) and kidney failure requiring 
KRT (3.9 million), an intimidating figure that is twice the estimated amount of people with 
diabetes on a global scale [147]. According to The Global Burden of Diseases, Injuries, and 
Risk Factors Study (GBD), 1.4 million people died from CKD in 2019 with an increase of 
28.8% since 2010, rendering CKD as the 11th leading cause of deaths globally [148]. While 
kidney dysfunction as such is a major contributor to morbidity and mortality, by increasing the 
risks associated with other leading causes of death worldwide (including CVD, cancer and 
diabetes), CKD per se is projected to be the 5th leading cause of global death by 2040 [149]. 
Global fatality from all kidney diseases could be even higher, reaching 5 million annually, and 
the lack or limited access to life-saving KRT is contributing to a rising fraction of deaths in 
low-middle-income countries (LMICs) [150]. In 2010, some 2.6 million people worldwide 
were receiving KRT with kidney failure whilst 2.3 to 7.1 million more people, mostly in 
LMICs, required KRT but died in need for it [151]. Kidney disease is also associated with 
tremendous health expenditures. According to the United States Renal Data System (USRDS) 
2020 annual report, total Medicare-related expenditures in USA for CKD in 2018 were $81 
billion (representing 22.3% of Medicare fee-for-service) including $49.2 billion due to kidney 
failure [152]. Timely identification and management of risk factors involved in CKD 
progression aiming at reducing its concerning fatality rate and growing global health care 
burden can clearly have a great social and economic impact.  
Of note, the major culprits of high morbidity and mortality in kidney dysfunction are attributed 
to its high prevalence of cardiovascular complications, which can be several-fold higher than 
in age-matched subjects without kidney failure. According to USRDS 2020 annual report 
[152], the prevalence of CVD was 76.5 % in HD patients, 65.0% in PD patients and 53.7% in 
patients with a functioning kidney transplant. Intriguingly, unlike in the general population 
where coronary atherosclerosis disease is the dominant cause of CV mortality, patients with 
CKD also exhibited a large proportion of left ventricular hypertrophy (LVH) driven by 
progressive VC as the most apparent cardiovascular abnormality [117,153–156]. Many 
therapeutic strategies targeting VC have therefore been explored and evaluated, including 
controlling athero- and arteriosclerosis and managing CKD-MBD. So far, the results are 
inconclusive and it remains unclear whether they are efficient in mitigating VC progression 
[4]. Prior to these problem-solving yet off-target attempts, it is possible that we may have 
missed out the full picture of VC in the context of CKD. The studies presented in this thesis 
further explore the prognostic value, predictive markers as well as treatment consequence of 
VC in uremic milieus. A better understanding of the clinical relevance of VC could advance 
the development of efficient preventive and therapeutic strategies, and ultimately exert a 
beneficial effect on the kidney health-related social and economic burden.  
For instance, in Study I, in contrast to what observed in general population, we found an inverse 
J-shaped pattern between CAC density and mortality, which suggests a more complex scenario 
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between CAC density, volume and risk prediction in the uremic milieu. In Study II, we found 
a strong predictive value of AVC for mortality over traditional risk factors and inflammation, 
suggesting that AVC might be potentially included in the standard risk evaluation. From a 
scientific point of view, these findings provide a new perspective of the prognostic value of 
CAC and AVC, which can guide long-term prospective studies to evaluate the joint impact of 
evolution of CAC components, AVC, concomitant media calcification and other potential risk 
factors on clinical outcome. Additionally, from an economic point of view, our findings reflect 
potential large cost-effectiveness gains by a wider use of cardiovascular imaging in screening 
and risk stratification in advanced CKD. Clearly, more solid evidence is required to determine 
the clinical value of cardiovascular imaging, taking into account the current technique 
challenge of stratifying calcium density and volume, differentiating intima/media VC and 
identifying micro- and macrocalcification. It can be speculated that while overuse may generate 
a harmless yet redundant information, it will add extra costs and burden the health care system; 
underuse, on the other hand, may lead to a failure to collect critical information needed to 
diagnose and implement therapeutic strategies. Misuse, in this sense, without knowing the true 
role of calcium score in risk prediction, could drive false and misleading conclusions, both at 
a scientific level and in clinical practice, with similar unfavorable consequences as overuse and 
underuse.  
In Study III, we identified 17 features including traditional risk factors and novel biomarkers 
associated with histologically verified media VC using the RLS method. Given the high 
prevalence of media VC and its critical impact on the development of arterial stiffening and 
LVH, predictions based on early and accurate diagnosis of media VC is vital in improving 
cardiovascular outcomes in CKD. Techniques quantifying media VC in clinical practice are 
however not available. Hence, alternative new generation data analysis methodology and 
machine-learning algorithms that are able to integrate biomarkers with mechanistic and 
imaging data to predict and quantitate the presence and extent of media VC - and more 
importantly - to discover novel therapeutic targets, are urgently needed. Echoing this, we 
applied the advanced mathematic modelling of the RLS method and provided a holistic as well 
as a less biased view of potential risk factors that concomitantly associate with presence of VC. 
Although the validation of phenotypic features associated with biopsy-verified vascular media 
VC requires replication in other cohorts, our findings may facilitate future investigations on 
media VC without taking arterial biopsies. This non-invasive machine-learning exploration 
exemplifies a potential cost-effective strategy with possible maximum benefits to patients, 
clinicians, policymakers and health care system as a whole.  
In Study IV, we found an association between sevelamer use and disturbed microbial 
metabolism, suggesting clinical trade-offs of sevelamer therapy beyond its phosphate control 
benefits. This delivers an important message to clinicians and researchers of potential drug-bug 
interaction. In fact, a recent survey revealed that up to 24% of drugs may affect the gut 
microbiome [51]. Thus, it is conceivable that a better knowledge of drug-bug interactions may 
open new paths for side effect control.  
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In Study V, we found that dp-ucMGP did not correlate with VC but significantly associated 
with the study endpoint, i.e., all-cause mortality.  Whereas the “non-positive” finding of non- 
apparent association between dp-ucMGP and VC might be attributed to study design, the 
association of dp-ucMGP with mortality may be more important when assessing the impact of 
this research. In scientific explorations, the obtained results are not always equivalent to 
expected ones. Taking account into the study-specific conditions (e.g., study design, 
methodology and limitations), our finding may encourage and add value to future research 
about the role of vitamin K deficiency in cardiovascular health, as well as its less explored 
function in mediating non-cardiovascular causes of poor outcomes in the context of CKD. 
Taken together, we performed observational studies to expand the knowledge of risk factors 
and prognostic value of VC in the context of CKD. We observed several novel and intriguing 
associations that, as a next step, may guide the design of longitudinal explorations,  
interventional and mechanistic studies, aiming at establishing causal relationships and possibly 
leading to improved diagnostic, preventive and therapeutic strategies for this severe 
complication of CKD. Also, it is worth to note that in the pandemic of coronavirus disease-
2019 (COVID-19), several reports have indicated that VC detected by chest CT, such as the 
presence and extent of CAC and the volume of aortic wall calcification, is a predictor of severe 
COVID-19 and associated with worse prognosis in hospitalized patients with COVID-19 
[157,158]. Therefore, aside from the focus on CKD, the role of VC in risk stratification and 
prognosis in other disease scenarios is to be explored and highlighted.  
The studies presented in the thesis are available to the public in peer-reviewed journals and the 
results have been largely disseminated and shared with scientific community through posters 
and oral presentations at several international conferences, symposiums, and other meetings. 
Aside from scientific aspects, findings reported in this thesis may bring several of the above-
mentioned reflections to researchers, medical community, policymakers and health care 
managers above the boom and bust of cardiovascular imaging, the potentials of mathematical 
modeling in cardiovascular research, the interactions between drugs and microbes in 












I have incurred many debts in writing this thesis. And my sense of gratitude, especially to those 
who have supported and encouraged my research activities during the last four years, is very 
deep. First to my main supervisor, Peter Stenvinkel, who has been extremely supportive by 
constantly helping and guiding me through this research journey with his scientific insights, 
inspirations and enthusiasms – his knowledge, decency and integrity shall never fail to impress 
me. To Bengt Lindholm, my co-supervisor who has shed much light on my both academic 
and personal development. In particular, his visions and advice set me straight at some 
particular crossroads wanderings in research, culture and life. His unprecedented tolerance has 
allowed me to explore the seemingly impossible possible, for which I am very grateful. I am 
indebted as well to my co-supervisor Abdul Rashid (Tony) Qureshi, for his generous teaching 
of statistics and patient responses to my plaintive demands for particular documents. Without 
his moral support and ruthless critique, I might never have enjoyed this journey. A special 
homage to Tony’s office room, a cosmos of scientific arguments, philosophical discussions and 
hearty companionship, from which developed our sincere friendship. And to my co-supervisor 
Anna Witasp, who has shared and introduced laboratory techniques and provide prompt help 
whenever needed. I am also most grateful to Leon Schurgers, my supervisor at Maastricht 
University, who has always been cheerful, inspiring and supportive. 
Many thanks are also due to a team of collaborators from Warsaw, Poland, who have always 
kindly received our visiting at their institution and have generously shared their mathematic 
knowledge. Aside from scientific talents and merits, I have also profited from conversations 
with Jacek Waniewski, who has enlightened me with nature exploration as a remedy for my 
puzzling moments in life and research. Malgorzata Debowska – a brilliant friend and scientist 
with less words but more actions, has been unfailingly patient, helpful and thorough in carrying 
out what sometimes seemed daunting tasks. My thanks also go to other researchers in this 
group, Jan Poleszczuk, Joanna Stachowska-Pietka, Mauro Pietribiasi, Tomasz Lukaszuk and 
Leon Bobrowski, for their considerable erudition and inspirations.  
Without the supportive work of Jonaz Ripsweden, who has given unstintingly his time in 
reading and extracting imaging data and has generously shared his knowledge of imaging in a 
series of lengthy meetings, I would not have been able to sort out the manuscripts on cardiac 
calcium score. Through those humble discussions mixed with joyful anecdotes, comes along 
more embryonic research ideas that we have not been able to implement at the time of writing 
this thesis, but certainly it will be a continuation of scientific explorations. Also, I would like 
to thank Torkel B. Brismar, who has encouraged me in scientific research and jointly 
contributed critical inputs in imaging data exploration.  
I would like to thank the consortium of International Network for Training on Risks of Vascular 
Intimal Calcification and Roads to Regression of Cardiovascular Disease (INTRICARE, 
European Union’s Horizon 2020 research and innovation program under the Marie 
Skłodowska-Curie grant No 722609) for giving me the opportunity to get to know fantastic 
groups of researchers, to communicate and to learn science at its best. INTRICARE consortium 
 
 33 
has also supported and made it possible for me to visit and learn at Department of 
Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, 
which opens my eyes to exciting molecule world of lab activities. I have received help from 
my supervisor Leon Schurgers and his lab team members in various aspects. I would give 
special thanks to Cengiz Akbulut, who has warmly instructed me to the lab work and 
knowledge with exemplary calm and patience. Nikolas Rapp, who were also generous with 
time, has given me kind instructions. My gratitude also goes to Grzegorz Wasilewski, Dawid 
Kaczor, Rogier Veltrop, and Selene Prisco, with whom I have spent lovely time both at and off 
work. I also would like to express my appreciation for those whosoever has given help and 
companionship during my stay in Maastricht, to Mueez Aizaz, Armand Jaminon, Rick van 
Gorp, Ploingarm Petsophonsakul, Angelina Pavlic, Petro Lux, Niko Deckers, Chris 
Reutelingsperger, Cecile Maassen, Gosia Furmanik, Lisette Ungethüm, Hessel Poelman, 
Anouk Gentier, Alice Todaro, Robin Colpaert, Nicolò Mangraviti, Gina Perrella, Delia 
Fernandez, Xiaosong Liu, Jingnan Huang, Trees Camphuisen, Tilman Hackeng, Stella 
Thomassen, Elisabetta Castoldi, Hans Ippel and many others with whom I may speak only 
briefly were nevertheless always inspiring. In addition to some of those mentioned, I would 
like to express my appreciation to all other members and researchers in INTRICARE 
consortium, where we have shared knowledge and spent wonderful time, Magnus Bäck, Rory 
Koenen, Joachim Jankowski, Caludia Goettsch, Ulf Hedin, Ljubica Matic, Erik Biessen, Eline 
Kooi, Felix Mottaghy, Wilhelm Jahnen-Dechent, Johan Frostegård, Sébastien Foulquier, 
Jürgen Floege, Cathy Shanahan, Shruti Bhargava, Nikos Skenteris, Marina Heuschkel, 
Shailesh Samal, Till Seime, Stefan Reimbold, Maurice Halder, Olivia Waring, Robert 
Dzhanaev and Alexandru Florea. My thanks also go to Tara de Koster, who has provided help 
and coordination in INTRICARE consortium and made our life easier.   
I would especially like to acknowledge some research collaborators and co-authors involved 
in this work. To Pieter Evenepoel, for his enlightening knowledge and considerable critique, 
from which I have benefited in improving the studies. To Magnus Bäck, who has brought up 
nice research ideas and encouraged me to explore the data. To Magnus Söderberg, who has 
contributed to histological calcium scoring in the biobank. In addition, I would also like to 
thank Peter Barany, Olof Heimbürger, Oscar Plunde, Henriette de Loor, Björn Meijers, Bert 
Bammens, Hanne Skou Jørgensen and Paul Shiels for providing valuable comments and 
suggestions in the manuscripts. 
I am grateful to our research staff at KBC Sofie Garpemo, Ulrika Jensen Durgé, Yvonne 
Ekelöw, Annika Nilsson and at Renal Lab Björn Anderstam, Monica Ericsson and Anki 
Bragfors-Helin. This work presented would be impossible without their efforts on sample 
analyses over the years. Also, I would like to convey my thanks to my mentor Hong Xu, for 
her encouragement and warm help and to my colleagues at Renal Medicine, Karolina 
Kublickiene, Thomas Ebert, Samsul Arefin, Sam Hobson, Angelina Schwarz, Liam Ward, and 




I will always remain affectionately grateful to Baxter Novum, which has brought exuberant 
international researchers and friends and working opportunities. The routine lunch table we 
have shared is a big family style for relaxing at noon, and a following fika session characterized 
often with dynamic collection of local and international sweets derives all crazy yet joyful chats 
and laughs. Had I made a record of these anecdotes over the time, volumes of A Lunch Table 
Almanac would be achieved. I deeply regret that I did not do so. Many friends visiting Baxter 
Novum have made my stay spiritually cheerful and culturally fruitful - those reflections of 
gaiety in working place become more precious during the social-distance pandemic era at the 
time of writing this thesis. Among those visiting friends I would like to mention Ken Iseri, 
Hideyuki Mukai, Kei Nagai, Xin Li, Xianfeng Wu, Longkai Li, Hokuto Morohoshi, Akiko 
Morohoshi, Jia Sun, Elvia Garcia-Lopez, Feyza Bora, Nuri Baris Hasbal, Doris Chan, José 
Divino, Hilda Villafuerte, Gabriela Cobo, Fabiola Alonso, Erika Gómez, Magdalena 
Jankowska, Sawako Kato, Edyta Golembiewska, Amaryllis Van Craenenbroeck, Carla 
Avesani and Anna Machowska. Also, special thanks to Linn Berg, who has helped me to 
coordinate and communicate many issues to make my life more workable. 
I would like to express my personal and professional gratitude to my Brazilian friend Denise 
Mafra, whom I met at Baxter Novum for a rather short time period but later developed a solid 
friendship. Her distinctively exuberant energy both in life and in research opens my eyes 
towards new codes of life as well as to the unlimited exploration of micronutrients. I am also 
especially grateful to Evianne Larsson, who has helped me to hold on faith in work, culture 
and life through so many hearty conversations. Her moral virtue and justice are enormously 
precious and I feel blessed to have such a bond of friendship with her.  
Closer to my homeland, I would like to thank all my friends and mentors with whom I have 
been in close touch during the last four years. Every time I visited them in China with various 
locations, I feel like comfy home. I am truly grateful to have their support and friendship.  
Finally, I wish to thank my dear family, my mother and my father, who have been closely 
supporting and encouraging me all around, are always the first choice of candidates that I have 
shared with my sweet and sorrow over the years. My sister and her family - my brother-in-law 
and my two darling nieces, their loving mind and character and support, are a treasure and 
shelter in my life.  









1. Stenvinkel P, Larsson TE. Chronic kidney disease: A clinical model of premature aging. Am 
J Kidney Dis 2013; 62: 339–51. 
2. Kooman JP, Kotanko P, Schols AMWJ, Shiels PG, Stenvinkel P. Chronic kidney disease 
and premature ageing. Nat Rev Nephrol 2014; 10: 732–42. 
3. Shanahan CM. Mechanisms of vascular calcification in CKD-evidence for premature 
ageing? Nat Rev Nephrol 2013; 9: 661–70. 
4. Wu M, Rementer C, Giachelli CM. Vascular Calcification: An Update on Mechanisms and 
Challenges in Treatment. Calcif Tissue Int 2013; 93: 365–73. 
5. Raggi P, Bellasi A, Bushinsky D, et al. Slowing Progression of Cardiovascular Calcification 
With SNF472 in Patients on Hemodialysis. Circulation 2020; 141: 728–39. 
6. Voelkl J, Luong TTDT, Tuffaha R, et al. SGK1 induces vascular smooth muscle cell 
calcification through NF-κB signaling. J Clin Invest 2018; 128: 3024–40. 
7. Gilham D, Tsujikawa LM, Sarsons CD, et al. Apabetalone downregulates factors and 
pathways associated with vascular calcification. Atherosclerosis 2019; 280: 75–84. 
8. Boenink R, Stel VS, Waldum-Grevbo BE, et al. Data from the ERA-EDTA Registry were 
examined for trends in excess mortality in European adults on kidney replacement therapy. 
Kidney Int 2020; 98: 999–1008. 
9. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M, Detrano R. 
Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll 
Cardiol 1990; 15: 827–32. 
10. Matsushita K, Sang Y, Ballew SH, et al. Subclinical Atherosclerosis Measures for 
Cardiovascular Prediction in CKD. J Am Soc Nephrol 2015; 26: 439–47. 
11. Forbang NI, Michos ED, McClelland RL, et al. Greater Volume but not Higher Density of 
Abdominal Aortic Calcium Is Associated with Increased Cardiovascular Disease Risk: MESA 
(Multi-Ethnic Study of Atherosclerosis). Circ Cardiovasc Imaging 2016; 9: 1–6. 
12. Thomas IC, McClelland RL, Allison MA, et al. Progression of calcium density in the 
ascending thoracic aorta is inversely associated with incident cardiovascular disease events. 
Eur Hear J - Cardiovasc Imaging 2018; 19: 1343–50. 
13. Criqui MH, Denenberg JO, Ix JH, et al. Calcium Density of Coronary Artery Plaque and 
Risk of Incident Cardiovascular Events. JAMA 2014; 311: 271. 
14. Bellasi A, Ferramosca E, Ratti C, Block G, Raggi P. The density of calcified plaques and 
the volume of calcium predict mortality in hemodialysis patients. Atherosclerosis 2016; 250: 
166–71. 
15. Raffield LM, Cox AJ, Criqui MH, et al. Associations of coronary artery calcified plaque 
density with mortality in type 2 diabetes: the Diabetes Heart Study. Cardiovasc Diabetol 2018; 
17: 67. 
16. Aikawa E, Nahrendorf M, Figueiredo J-L, et al. Osteogenesis Associates With 
Inflammation in Early-Stage Atherosclerosis Evaluated by Molecular Imaging In Vivo. 
Circulation 2007; 116: 2841–50. 
 
36 
17. Vengrenyuk Y, Carlier S, Xanthos S, et al. A hypothesis for vulnerable plaque rupture due 
to stress-induced debonding around cellular microcalcifications in thin fibrous caps. Proc Natl 
Acad Sci 2006; 103: 14678–83. 
18. Mauriello A, Servadei F, Zoccai GB, et al. Coronary calcification identifies the vulnerable 
patient rather than the vulnerable Plaque. Atherosclerosis 2013; 229: 124–9. 
19. Virmani R, Burke AP, Kolodgie FD, Farb A. Pathology of the thin-cap fibroatheroma: a 
type of vulnerable plaque. J Interv Cardiol 2003; 16: 267–72. 
20. Houslay ES, Cowell SJ, Prescott RJ, et al. Progressive coronary calcification despite 
intensive lipid-lowering treatment: a randomised controlled trial. Heart 2006; 92: 1207–12. 
21. Puri R, Nicholls SJ, Shao M, et al. Impact of statins on serial coronary calcification during 
atheroma progression and regression. J Am Coll Cardiol 2015; 65: 1273–82. 
22. Tenenbaum A, Shemesh J, Koren-Morag N, et al. Long-term changes in serum cholesterol 
level does not influence the progression of coronary calcification. Int J Cardiol 2011; 150: 
130–4. 
23. Rodriguez-Granillo GA, Carrascosa P, Bruining N. Progression of coronary artery 
calcification at the crossroads: Sign of progression or stabilization of coronary atherosclerosis? 
Cardiovasc Diagn Ther 2016; 6: 250–8. 
24. Mizobuchi M, Towler D, Slatopolsky E. Vascular calcification: the killer of patients with 
chronic kidney disease. J Am Soc Nephrol 2009; 20: 1453–64. 
25. Vervloet M, Cozzolino M. Vascular calcification in chronic kidney disease: different bricks 
in the wall? Kidney Int 2017; 91: 808–17. 
26. Yamada S, Taniguchi M, Tokumoto M, et al. The antioxidant tempol ameliorates arterial 
medial calcification in uremic rats: important role of oxidative stress in the pathogenesis of 
vascular calcification in chronic kidney disease. J Bone Miner Res 2012; 27: 474–85. 
27. McCabe KM, Booth SL, Fu X, et al. Dietary vitamin K and therapeutic warfarin alter the 
susceptibility to vascular calcification in experimental chronic kidney disease. Kidney Int 2013; 
83: 835–44. 
28. Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM. Arterial calcification in 
chronic kidney disease: key roles for calcium and phosphate. Circ Res 2011; 109: 697–711. 
29. Vaziri ND. Oxidative stress in uremia: nature, mechanisms, and potential consequences. 
Semin Nephrol 2004; 24: 469–73. 
30. Kaesler N, Goettsch C, Weis D, et al. Magnesium but not nicotinamide prevents vascular 
calcification in experimental uraemia. Nephrol Dial Transplant 2020; 35: 65–73. 
31. Dai L, Qureshi AR, Witasp A, Lindholm B, Stenvinkel P. Early Vascular Ageing and 
Cellular Senescence in Chronic Kidney Disease. Comput Struct Biotechnol J 2019; 17: 721–9. 
32. Laurent S, Cockcroft J, Van Bortel L, et al. Expert consensus document on arterial stiffness: 
methodological issues and clinical applications. Eur Heart J 2006; 27: 2588–605. 
33. Boutouyrie P, Bruno R-M. The Clinical Significance and Application of Vascular Stiffness 
Measurements. Am J Hypertens 2019; 32: 4–11. 
34. Manzoor S, Ahmed S, Ali A, et al. Progression of Medial Arterial Calcification in CKD. 
 
 37 
Kidney Int Reports 2018; 3: 1328–35. 
35. O’Seaghdha CM, Hwang S-J, Muntner P, Melamed ML, Fox CS. Serum phosphorus 
predicts incident chronic kidney disease and end-stage renal disease. Nephrol Dial Transplant 
2011; 26: 2885–90. 
36. Chang WX, Xu N, Kumagai T, et al. The Impact of Normal Range of Serum Phosphorus 
on the Incidence of End-Stage Renal Disease by A Propensity Score Analysis. PLoS One 2016; 
11: e0154469. 
37. Giachelli CM. The emerging role of phosphate in vascular calcification. Kidney Int 2009; 
75: 890–7. 
38. Nasrallah MM, El-Shehaby AR, Salem MM, Osman NA, El Sheikh E, Sharaf El Din UA. 
Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in 
haemodialysis patients. Nephrol Dial Transplant 2010; 25: 2679–85. 
39. Scialla JJ, Lau WL, Reilly MP, et al. Fibroblast growth factor 23 is not associated with and 
does not induce arterial calcification. Kidney Int 2013; 83: 1159–68. 
40. Lim K, Lu T-S, Molostvov G, et al. Vascular Klotho Deficiency Potentiates the 
Development of Human Artery Calcification and Mediates Resistance to Fibroblast Growth 
Factor 23. Circulation 2012; 125: 2243–55. 
41. Jimbo R, Kawakami-Mori F, Mu S, et al. Fibroblast growth factor 23 accelerates 
phosphate-induced vascular calcification in the absence of Klotho deficiency. Kidney Int 2014; 
85: 1103–11. 
42. Cannata-Andía JB, Fernández-Martín JL, Locatelli F, et al. Use of phosphate-binding 
agents is associated with a lower risk of mortality. Kidney Int 2013; 84: 998–1008. 
43. Chertow GM, Burke SK, Raggi P, Treat to Goal Working Group. Sevelamer attenuates the 
progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 
245–52. 
44. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary 
calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007; 
71: 438–41. 
45. Susantitaphong P, Jaber BL. Potential interaction between sevelamer and fat-soluble 
vitamins: a hypothesis. Am J kidney Dis 2012; 59: 165–7. 
46. Jansz TT, Neradova A, Van Ballegooijen AJ, et al. The role of kidney transplantation and 
phosphate binder use in vitamin K status. PLoS One 2018; 13: 1–13. 
47. Takagi K, Masuda K, Yamazaki M, et al. Metal ion and vitamin adsorption profiles of 
phosphate binder ion-exchange resins. Clin Nephrol 2010; 73: 30–5. 
48. Magee J, Robles M, Dunaway P. Sevelamer-Induced Gastrointestinal Injury Presenting as 
Gastroenteritis. Case Rep Gastroenterol 2018; 12: 41–5. 
49. Swanson BJ, Limketkai BN, Liu TC, et al. Sevelamer crystals in the gastrointestinal tract 
(GIT): A new entity associated with mucosal injury. Am J Surg Pathol 2013; 37: 1686–93. 
50. Yuste C, Mérida E, Hernández E, et al. Gastrointestinal complications induced by 
sevelamer crystals. Clin Kidney J 2017; 10: 539–44. 
 
38 
51. Maier L, Pruteanu M, Kuhn M, et al. Extensive impact of non-antibiotic drugs on human 
gut bacteria. Nature 2018; 555: 623–8. 
52. Price PA, Urist MR, Otawara Y. Matrix Gla protein, a new γ-carboxyglutamic acid-
containing protein which is associated with the organic matrix of bone. Biochem Biophys Res 
Commun 1983; 117: 765–71. 
53. Luo G, Ducy P, McKee MD, et al. Spontaneous calcification of arteries and cartilage in 
mice lacking matrix GLA protein. Nature 1997; 386: 78–81. 
54. Munroe PB, Olgunturk RO, Fryns J-P, et al. Mutations in the gene encoding the human 
matrix Gla protein cause Keutel syndrome. Nat Genet 1999; 21: 142–4. 
55. Teebi AS, Lambert DM, Kaye GM, Al-Fifi S, Tewfik TL, Azouz EM. Keutel syndrome: 
further characterization and review. Am J Med Genet 1998; 78: 182–7. 
56. O’Young J, Liao Y, Xiao Y, et al. Matrix Gla Protein Inhibits Ectopic Calcification by a 
Direct Interaction with Hydroxyapatite Crystals. J Am Chem Soc 2011; 133: 18406–12. 
57. Zebboudj AF, Imura M, Boström K. Matrix GLA Protein, a Regulatory Protein for Bone 
Morphogenetic Protein-2. J Biol Chem 2002; 277: 4388–94. 
58. Yao Y, Zebboudj AF, Shao E, Perez M, Boström K. Regulation of Bone Morphogenetic 
Protein-4 by Matrix GLA Protein in Vascular Endothelial Cells Involves Activin-like Kinase 
Receptor 1. J Biol Chem 2006; 281: 33921–30. 
59. Murshed M, Schinke T, McKee MD, Karsenty G. Extracellular matrix mineralization is 
regulated locally; different roles of two gla-containing proteins. J Cell Biol 2004; 165: 625–30. 
60. Schurgers LJ, Spronk HMH, Skepper JN, et al. Post-translational modifications regulate 
matrix Gla protein function: Importance for inhibition of vascular smooth muscle cell 
calcification. J Thromb Haemost 2007; 5: 2503–11. 
61. Shearer MJ. Vitamin K. Lancet 1995; 345: 229–34. 
62. Ueland T, Gullestad L, Dahl CP, et al. Undercarboxylated matrix Gla protein is associated 
with indices of heart failure and mortality in symptomatic aortic stenosis. J Intern Med 2010; 
268: 483–92. 
63. Mayer O, Seidlerová J, Bruthans J, et al. Desphospho-uncarboxylated matrix Gla-protein 
is associated with mortality risk in patients with chronic stable vascular disease. 
Atherosclerosis 2014; 235: 162–8. 
64. Mayer O, Seidlerová J, Vaněk J, et al. The abnormal status of uncarboxylated matrix Gla 
protein species represents an additional mortality risk in heart failure patients with vascular 
disease. Int J Cardiol 2016; 203: 916–22. 
65. Schurgers LJ, Barreto D V., Barreto FC, et al. The Circulating Inactive Form of Matrix Gla 
Protein Is a Surrogate Marker for Vascular Calcification in Chronic Kidney Disease: A 
Preliminary Report. Clin J Am Soc Nephrol 2010; 5: 568–75. 
66. Keyzer CA, Vermeer C, Joosten MM, et al. Vitamin K status and mortality after kidney 
transplantation: A cohort study. Am J Kidney Dis 2015; 65: 474–83. 
67. Roumeliotis S, Roumeliotis A, Panagoutsos S, et al. Matrix Gla protein T-138C 
polymorphism is associated with carotid intima media thickness and predicts mortality in 
patients with diabetic nephropathy. J Diabetes Complications 2017; 31: 1527–32. 
 
 39 
68. Dalmeijer GW, van der Schouw YT, Magdeleyns EJ, et al. Matrix Gla Protein Species and 
Risk of Cardiovascular Events in Type 2 Diabetic Patients. Diabetes Care 2013; 36: 3766–71. 
69. Liu Y-P, Gu Y-M, Thijs L, et al. Inactive Matrix Gla Protein Is Causally Related to Adverse 
Health Outcomes. Hypertension 2015; 65: 463–70. 
70. Riphagen I, Keyzer C, Drummen N, et al. Prevalence and Effects of Functional Vitamin K 
Insufficiency: The PREVEND Study. Nutrients 2017; 9: 1334. 
71. O’Donnell CJ, Shea MK, Price PA, et al. Matrix Gla Protein Is Associated With Risk 
Factors for Atherosclerosis but not With Coronary Artery Calcification. Arterioscler Thromb 
Vasc Biol 2006; 26: 2769–74. 
72. Delanaye P, Krzesinski J-M, Warling X, et al. Dephosphorylated-uncarboxylated Matrix 
Gla protein concentration is predictive of vitamin K status and is correlated with vascular 
calcification in a cohort of hemodialysis patients. BMC Nephrol 2014; 15: 145. 
73. Shroff RC, Shah V, Hiorns MP, et al. The circulating calcification inhibitors, fetuin-A and 
osteoprotegerin, but not Matrix Gla protein, are associated with vascular stiffness and 
calcification in children on dialysis. Nephrol Dial Transplant 2008; 23: 3263–71. 
74. Thamratnopkoon S, Susantitaphong P, Tumkosit M, et al. Correlations of Plasma 
Desphosphorylated Uncarboxylated Matrix Gla Protein with Vascular Calcification and 
Vascular Stiffness in Chronic Kidney Disease. Nephron 2017; 135: 167–72. 
75. De Vriese AS, Caluwé R, Pyfferoen L, et al. Multicenter Randomized Controlled Trial of 
Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in 
Hemodialysis Patients with Atrial Fibrillation: the Valkyrie Study. J Am Soc Nephrol 2019: 
ASN.2019060579. 
76. Witham MD, Lees JS, Myra W, et al. Vitamin K Supplementation to Improve Vascular 
Stiffness in CKD: The K4Kidneys Randomized Controlled Trial. J Am Soc Nephrol 2020; 31. 
77. Shea MK, Loeser RF, Hsu F-C, et al. Vitamin K Status and Lower Extremity Function in 
Older Adults: The Health Aging and Body Composition Study. Journals Gerontol Ser A Biol 
Sci Med Sci 2016; 71: 1348–55. 
78. Machado-Fragua MD, Hoogendijk EO, Struijk EA, et al. High dephospho-uncarboxylated 
matrix Gla protein concentrations, a plasma biomarker of vitamin K, in relation to frailty: the 
Longitudinal Aging Study Amsterdam. Eur J Nutr 2019. 
79. Wei F-F, Drummen NEA, Schutte AE, et al. Vitamin K Dependent Protection of Renal 
Function in Multi-ethnic Population Studies. EBioMedicine 2016; 4: 162–9. 
80. Puzantian H, Akers SR, Oldland G, et al. Circulating Dephospho-Uncarboxylated Matrix 
Gla-Protein Is Associated With Kidney Dysfunction and Arterial Stiffness. Am J Hypertens 
2018; 31: 988–94. 
81. Stenvinkel P, Heimbürger O, Paultre F, et al. Strong association between malnutrition, 
inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55: 1899–911. 
82. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration 
rate. Ann Intern Med 2009; 150: 604–12. 
83. D’Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use 
in primary care: the Framingham Heart Study. Circulation 2008; 117: 743–53. 
 
40 
84. Qureshi AR, Alvestrand A, Danielsson A, et al. Factors predicting malnutrition in 
hemodialysis patients: a cross-sectional study. Kidney Int 1998; 53: 773–82. 
85. Durnin JVGA, Womersley J. Body fat assessed from total body density and its estimation 
from skinfold thickness: measurements on 481 men and women aged from 16 to 72 Years. Br 
J Nutr 1974; 32: 77–97. 
86. Siri WE. Body composition from fluid spaces and density: analysis of methods. 1961. 
Nutrition 1961; 9: 480-91, 492. 
87. Kyle UG, Schutz Y, Dupertuis YM, Pichard C. Body composition interpretation. 
Contributions of the fat-free mass index and the body fat mass index. Nutrition 2003; 19: 597–
604. 
88. Jaminon AMG, Dai L, Qureshi AR, et al. Matrix Gla protein is an independent predictor 
of both intimal and medial vascular calcification in chronic kidney disease. Sci Rep 2020; 10: 
1–9. 
89. de Loor H, Poesen R, De Leger W, et al. A liquid chromatography - tandem mass 
spectrometry method to measure a selected panel of uremic retention solutes derived from 
endogenous and colonic microbial metabolism. Anal Chim Acta 2016; 936: 149–56. 
90. Bobrowski L, Lukaszuk T. Feature Selection Based on Relaxed Linear Separability. 
Biocybern Biomed Eng 2009; 29: 43–59. 
91. Bobrowski L, Lukaszuk T. Selection of the Linearly Separable Feature subsets. Artif Intell 
Soft Comput 2004; 3070: 544–9. 
92. Cooper BA, Bartlett LH, Aslani A, Allen BJ, Ibels LS, Pollock CA. Validity of subjective 
global assessment as a nutritional marker in end-stage renal disease. Am J Kidney Dis 2002; 
40: 126–32. 
93. Steiber A, Leon JB, Secker D, et al. Multicenter study of the validity and reliability of 
subjective global assessment in the hemodialysis population. J Ren Nutr 2007; 17: 336–42. 
94. Group C-U (CANUSA) PDS. Adequacy of dialysis and nutrition in continuous peritoneal 
dialysis: association with clinical outcomes. Canada-USA (CANUSA) Peritoneal Dialysis 
Study Group. J Am Soc Nephrol 1996; 7: 198–207. 
95. Dai L, Mukai H, Lindholm B, et al. Clinical global assessment of nutritional status as 
predictor of mortality in chronic kidney disease patients. Kunze G, ed. PLoS One 2017; 12: 
e0186659. 
96. Seyahi N, Kahveci A, Cebi D, et al. Coronary artery calcification and coronary ischaemia 
in renal transplant recipients. Nephrol Dial Transplant 2011; 26: 720–6. 
97. Matsuoka M, Iseki K, Tamashiro M, et al. Impact of high coronary artery calcification 
score (CACS) on survival in patients on chronic hemodialysis. Clin Exp Nephrol 2004; 8: 54–
8. 
98. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary 
calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007; 
71: 438–41. 
99. Bellasi A, Raggi P. Vascular imaging in chronic kidney disease. Curr Opin Nephrol 
Hypertens 2012; 21: 382–8. 
 
 41 
100. Schoenhagen P, Ziada KM, Kapadia SR, Crowe TD, Nissen SE, Tuzcu EM. Extent and 
Direction of Arterial Remodeling in Stable Versus Unstable Coronary Syndromes. Circulation 
2000; 101: 598–603. 
101. Leber AW, Knez A, White CW, et al. Composition of coronary atherosclerotic plaques in 
patients with acute myocardial infarction and stable angina pectoris determined by contrast-
enhanced multislice computed tomography. Am J Cardiol 2003; 91: 714–8. 
102. Shemesh J, Apter S, Itzchak Y, Motro M. Coronary Calcification Compared in Patients 
with Acute versus in Those with Chronic Coronary Events by Using Dual-Sector Spiral CT. 
Radiology 2003; 226: 483–8. 
103. Ehara S, Kobayashi Y, Yoshiyama M, et al. Spotty Calcification Typifies the Culprit 
Plaque in Patients With Acute Myocardial Infarction. Circulation 2004; 110: 3424–9. 
104. Hou Z, Lu B, Gao Y, et al. Prognostic Value of Coronary CT Angiography and Calcium 
Score for Major Adverse Cardiac Events in Outpatients. JACC Cardiovasc Imaging 2012; 5: 
990–9. 
105. Carrero JJ, Stenvinkel P. Persistent inflammation as a catalyst for other risk factors in 
chronic kidney disease: a hypothesis proposal. CJASN 2009; 4 Suppl 1: S49-55. 
106. Mukai H, Dai L, Chen Z, et al. Inverse J-shaped relation between coronary arterial calcium 
density and mortality in advanced chronic kidney disease. Nephrol Dial Transplant 2020; 35: 
1202–11. 
107. Kirsch AH, Kirsch A, Artinger K, et al. Heterogeneous susceptibility for uraemic media 
calcification and concomitant inflammation within the arterial tree. Nephrol Dial Transplant 
2015; 30: 1995–2005. 
108. Stewart BF, Siscovick D, Lind BK, et al. Clinical factors associated with calcific aortic 
valve disease. Cardiovascular Health Study. JACC 1997; 29: 630–4. 
109. Owens DS, Budoff MJ, Katz R, et al. Aortic valve calcium independently predicts 
coronary and cardiovascular events in a primary prevention population. JACC Cardiovasc 
Imaging 2012; 5: 619–25. 
110. Straumann E, Meyer B, Misteli M, Blumberg A, Jenzer HR. Aortic and mitral valve 
disease in patients with end stage renal failure on long-term haemodialysis. Br Heart J 1992; 
67: 236–9. 
111. Raggi P, Bellasi A, Gamboa C, et al. All-cause mortality in hemodialysis patients with 
heart valve calcification. CJASN 2011; 6: 1990–5. 
112. Leskinen Y, Paana T, Saha H, et al. Valvular calcification and its relationship to 
atherosclerosis in chronic kidney disease. J Heart Valve Dis 2009; 18: 429–38. 
113. Guerraty MA, Chai B, Hsu JY, et al. Relation of Aortic Valve Calcium to Chronic Kidney 
Disease (from the Chronic Renal Insufficiency Cohort Study). Am J Cardiol 2015; 115: 1281–
6. 
114. Cho KI, Sakuma I, Sohn IS, Jo S-H, Koh KK. Inflammatory and metabolic mechanisms 
underlying the calcific aortic valve disease. Atherosclerosis 2018; 277: 60–5. 
115. Dai L, Plunde O, Qureshi AR, et al. Aortic Valve Calcium Associates with All-Cause 
Mortality Independent of Coronary Artery Calcium and Inflammation in Patients with End-
 
42 
Stage Renal Disease. J Clin Med 2020; 9: 607. 
116. Drüeke TB, Massy ZA. Atherosclerosis in CKD: differences from the general population. 
Nat Rev Nephrol 2010; 6: 723–35. 
117. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media 
calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. 
Nephrol Dial Transpl 2003; 18: 1731–40. 
118. Dai L, Debowska M, Lukaszuk T, et al. Phenotypic features of vascular calcification in 
chronic kidney disease. J Intern Med 2020; 287: 422–34. 
119. Handelman GJ, Levin NW. Guidelines for vitamin supplements in chronic kidney disease 
patients: what is the evidence? J Ren Nutr 2011; 21: 117–9. 
120. Kaesler N, Magdeleyns E, Herfs M, et al. Impaired vitamin K recycling in uremia is 
rescued by vitamin K supplementation. Kidney Int 2014; 86: 286–93. 
121. Pilkey RM, Morton AR, Boffa MB, et al. Subclinical Vitamin K Deficiency in 
Hemodialysis Patients. Am J Kidney Dis 2007; 49: 432–9. 
122. Evenepoel P, Claes K, Meijers B, et al. Poor Vitamin K Status Is Associated With Low 
Bone Mineral Density and Increased Fracture Risk in End-Stage Renal Disease. J Bone Miner 
Res 2019; 34: 262–9. 
123. Wasilewski GB, Vervloet MG, Schurgers LJ. The Bone—Vasculature Axis: Calcium 
Supplementation and the Role of Vitamin K. Front Cardiovasc Med 2019; 6: 1–16. 
124. Neradova A, Schumacher SP, Hubeek I, Lux P, Schurgers LJ, Vervloet MG. Phosphate 
binders affect Vitamin K concentration by undesired binding, an in vitro study. BMC Nephrol 
2017; 18: 1–5. 
125. Fenn K, Strandwitz P, Stewart EJ, et al. Quinones are growth factors for the human gut 
microbiota. Microbiome 2017; 5: 161. 
126. Dai L, Meijers BK, Bammens B, et al. Sevelamer Use in End-Stage Kidney Disease 
(ESKD) Patients Associates with Poor Vitamin K Status and High Levels of Gut-Derived 
Uremic Toxins: A Drug–Bug Interaction? Toxins (Basel) 2020; 12: 351. 
127. Youssef B, Yan C, Dimitri TB, et al. The Effect of Sevelamer on Serum Levels of Gut-
Derived Uremic Toxins: Results from In Vitro Experiments and A Multicenter, Double-Blind, 
Placebo-Controlled, Randomized Clinical Trial. Toxins (Basel) 2019; 11: 1–12. 
128. De Smet R, Thermote F, Lamiere N. Sevelamer hydrochloride adsorbs the uremic 
compound indoxyl sulfate [abstract]. J Am Soc Nephrol 2003: 14: 206A. 
129. Brandenburg VM, Schlieper G, Heussen N, et al. Serological cardiovascular and mortality 
risk predictors in dialysis patients receiving sevelamer: A prospective study. Nephrol Dial 
Transplant 2010; 25: 2672–9. 
130. Block GA, Wheeler DC, Persky MS, et al. Effects of phosphate binders in moderate CKD. 
J Am Soc Nephrol 2012; 23: 1407–15. 
131. Evenepoel P, Meijers B. Chronic kidney disease: Phosphate binder therapy--cracks in the 
tower of strength? Nat Rev Nephrol 2012; 8: 615–6. 
132. Dalmeijer GW, van der Schouw YT, Vermeer C, Magdeleyns EJ, Schurgers LJ, Beulens 
 
 43 
JW. Circulating matrix Gla protein is associated with coronary artery calcification and vitamin 
K status in healthy women. J Nutr Biochem 2013; 24: 624–8. 
133. Schlieper G, Westenfeld R, Krüger T, et al. Circulating Nonphosphorylated Carboxylated 
Matrix Gla Protein Predicts Survival in ESRD. J Am Soc Nephrol 2011; 22: 387–95. 
134. Shea MK, O’Donnell CJ, Hoffmann U, et al. Vitamin K supplementation and progression 
of coronary artery calcium in older men and women. Am J Clin Nutr 2009; 89: 1799–807. 
135. Shea MK, O’Donnell CJ, Vermeer C, et al. Circulating Uncarboxylated Matrix Gla 
Protein Is Associated with Vitamin K Nutritional Status, but Not Coronary Artery Calcium, in 
Older Adults. J Nutr 2011; 141: 1529–34. 
136. Dai L, Li L, Erlandsson H, et al. Functional Vitamin K insufficiency, vascular calcification 
and mortality in advanced chronic kidney disease: A cohort study. PLoS One 2021; 16: 1–17. 
137. Dalmeijer GW, van der Schouw YT, Magdeleyns EJ, et al. Circulating desphospho-
uncarboxylated matrix γ-carboxyglutamate protein and the risk of coronary heart disease and 
stroke. J Thromb Haemost 2014; 12: 1028–34. 
138. McCann JC, Ames BN. Vitamin K, an example of triage theory: is micronutrient 
inadequacy linked to diseases of aging? Am J Clin Nutr 2009; 90: 889–907. 
139. van Ballegooijen AJ, van Putten SR, Visser M, Beulens JW, Hoogendijk EO. Vitamin K 
status and physical decline in older adults—The Longitudinal Aging Study Amsterdam. 
Maturitas 2018; 113: 73–9. 
140. Huang H, Liu PP, Hsu J, et al. Risk of Osteoporosis in Patients With Atrial Fibrillation 
Using Non–Vitamin K Antagonist Oral Anticoagulants or Warfarin. J Am Heart Assoc 2020; 
9. 
141. Mott A, Bradley T, Wright K, et al. Effect of vitamin K on bone mineral density and 
fractures in adults: an updated systematic review and meta-analysis of randomised controlled 
trials. Osteoporos Int 2019; 30: 1543–59. 
142. Bolzetta F, Veronese N, Stubbs B, et al. The Relationship between Dietary Vitamin K and 
Depressive Symptoms in Late Adulthood: A Cross-Sectional Analysis from a Large Cohort 
Study. Nutrients 2019; 11: 787. 
143. Shea MK, Barger K, Booth SL, et al. Vitamin K status, cardiovascular disease, and all-
cause mortality: a participant-level meta-analysis of 3 US cohorts. Am J Clin Nutr 2020; 111: 
1170–7. 
144. Pasch A, Farese S, Gräber S, et al. Nanoparticle-Based Test Measures Overall Propensity 
for Calcification in Serum. J Am Soc Nephrol 2012; 23: 1744–52. 
145. Laurent S, Boutouyrie P, Cunha PG, Lacolley P, Nilsson PM. Concept of Extremes in 
Vascular Aging. Hypertension 2019; 74: 218–28. 
146. Bruno RM, Nilsson PM, Engström G, et al. Early and Supernormal Vascular Aging. 
Hypertension 2020; 76: 1616–24. 
147. Kovesdy C, Langham R, Rosenberg M, Jha V. A single number for advocacy and 
communication-worldwide more than 850&nbsp;million individuals have kidney diseases. 
Kidney Int 2019; 96: 1048–50. 
148. Metrics GH. Global burden of 369 diseases and injuries in 204 countries and territories , 
 
44 
1990 – 2019 : a systematic analysis for the Global Burden of Disease Study 2019. 2020; 396. 
149. Foreman KJ, Marquez N, Dolgert A, et al. Forecasting life expectancy , years of life lost 
, and all-cause and cause-specific mortality for 250 causes of death : reference and alternative 
scenarios for 2016 – 40 for 195 countries and territories. Lancet 2018; 392: 2052–90. 
150. Harris DCH, Davies SJ, Finkelstein FO, et al. Increasing access to integrated ESKD care 
as part of universal health coverage. Kidney Int 2019; 95: S1–33. 
151. Liyanage T, Ninomiya T, Jha V, et al. Worldwide access to treatment for end-stage kidney 
disease: a systematic review. Lancet 2015; 385: 1975–82. 
152. Anon. 2020 USRDS Annual Data Report: Epidemiology of kidney disease in the United 
States. Bethesda, MD, 2020. 
153. London GM, Guerin AP, Marchais SJ, et al. Cardiac and arterial interactions in end-stage 
renal disease. Kidney Int 1996; 50: 600–8. 
154. London G, Covic A, Goldsmith D, et al. Arterial aging and arterial disease: interplay 
between central hemodynamics, cardiac work, and organ flow—implications for CKD and 
cardiovascular disease. Kidney Int Suppl 2011; 1: 10–2. 
155. Wang AY-M. Inflammation, Residual Kidney Function, and Cardiac Hypertrophy Are 
Interrelated and Combine Adversely to Enhance Mortality and Cardiovascular Death Risk of 
Peritoneal Dialysis Patients. J Am Soc Nephrol 2004; 15: 2186–94. 
156. Zoccali C, Benedetto FA, Mallamaci F, et al. Left ventricular mass monitoring in the 
follow-up of dialysis patients: Prognostic value of left ventricular hypertrophy progression. 
Kidney Int 2004; 65: 1492–8. 
157. Dillinger JG, Benmessaoud FA, Pezel T, et al. Coronary Artery Calcification and 
Complications in Patients With COVID-19. JACC Cardiovasc Imaging 2020; 13: 2468–70. 
158. Fervers P, Kottlors J, Zopfs D, et al. Calcification of the thoracic aorta on low-dose chest 













10 CURRICULUM VITAE  
About the author 
Lu Dai was born on December 21, 1989 in Shaoxing, China. After 
completing primary and secondary education in Shaoxing, she was 
enrolled in a seven-year medicine program (2007-2014) at Tianjin 
University of Traditional Chinese Medicine, Tianjin, China, during which 
she received Medical Doctor License (2013) and performed Master’s 
research (2012-2014). Her master’s thesis “Thrombin mediated renal 
interstitial fibrosis in obstructive nephropathy rat” was supervised by 
Prof. Hongtao Yang, at the Department of Nephrology at First Teaching 
Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China. After obtaining 
a Master of Medicine Degree in 2014, she continued research activities and clinical training 
under the supervision of Prof. Hongtao Yang at the Department of Nephrology (First Teaching 
Hospital of Tianjin University of Traditional Chinese Medicine). In 2016, she received a 
scholarship from China Scholarship Council (CSC) and was accepted as a visiting researcher 
at Division of Baxter Novum and Renal Medicine, Department of Clinical Science, 
Intervention and Technology, Karolinska Institutet, Stockholm, Sweden, supervised by Prof. 
Bengt Lindholm. Her research was focused on associations between malnutrition, 
inflammation, and clinical outcome in patients with chronic kidney disease. In 2017, she was 
accepted for PhD studies at Karolinska Institutet as part of the EU-funded International 
Network for Training on Risks of Vascular Intimal Calcification and roads to Regression of 
Cardiovascular Disease (INTRICARE) Marie-Curie program. Her PhD research has been 
focused on the comprehensive investigation on risk factors and prognostic values of premature 
vascular calcification in chronic kidney disease using bio-banking and clinical cohorts. The 
PhD project was performed under the supervision of Prof. Peter Stenvinkel, Prof. Bengt 
Lindholm, Dr. Abdul Rashid Qureshi and Dr. Anna Witasp at Karolinska Institutet and Prof. 
Leon Schurgers at Maastricht University. In 2019, she also performed a five-month 
secondment at the Department of Biochemistry, Cardiovascular Research School Maastricht 
(CARIM), Maastricht University, Maastricht, the Netherlands. Her research work conducted 
with joint scientific output in INTRICARE consortium is described in this thesis entitled 
“Chronic kidney disease - a clinical model of premature vascular aging”. 
 
Publications 
Dai L, Li L, Erlandsson H, Jaminon AMG, Qureshi AR, Ripsweden J, Brismar TB, Witasp A, 
Heimbürger O, Jørgensen HS, Barany P, Lindholm B, Evenepoel P, Schurgers LJ, Stenvinkel 
P. Functional Vitamin K insufficiency, vascular calcification and mortality in advanced chronic 
kidney disease: A cohort study. PLoS One. 2021;16(2 February):1-17.  
Kyriakidis NC, Cobo G, Dai L, Lindholm B, Stenvinkel P. Role of Uremic Toxins in Early 
Vascular Ageing and Calcification. Toxins (Basel). 2021 Jan 3;13(1):26.  
 
46 
Iseri K, Dai L, Chen Z, Qureshi AR, Brismar TB, Stenvinkel P, Lindholm B. Bone mineral 
density and mortality in end-stage renal disease patients. Clin Kidney J. 2020 Jun 26;13(3):307-
321.  
Dai L, Meijers BK, Bammens B, de Loor H, Schurgers LJ, Qureshi AR, Stenvinkel P, 
Evenepoel P. Sevelamer Use in End-Stage Kidney Disease (ESKD) Patients Associates with 
Poor Vitamin K Status and High Levels of Gut-Derived Uremic Toxins: A Drug-Bug 
Interaction? Toxins (Basel). 2020 May 27;12(6):351.  
Jaminon AMG, Dai L, Qureshi AR, Evenepoel P, Ripsweden J, Söderberg M, Witasp A, 
Olauson H, Schurgers LJ, Stenvinkel P. Matrix Gla protein is an independent predictor of both 
intimal and medial vascular calcification in chronic kidney disease. Sci Rep. 2020 Apr 
20;10(1):6586.  
Dai L, Schurgers LJ, Shiels PG, Stenvinkel P. Early vascular ageing in chronic kidney disease: 
impact of inflammation, vitamin K, senescence and genomic damage. Nephrol Dial Transplant. 
2020 Mar 1;35(Suppl 2): ii31-ii37.  
Dai L, Plunde O, Qureshi AR, Lindholm B, Brismar TB, Schurgers LJ, Söderberg M, 
Ripsweden J, Bäck M, Stenvinkel P. Aortic Valve Calcium Associates with All- Cause 
Mortality Independent of Coronary Artery Calcium and Inflammation in Patients with End-
Stage Renal Disease. J Clin Med. 2020 Feb 24;9(2):607.  
Golembiewska E, Qureshi AR, Dai L, Lindholm B, Heimbürger O, Söderberg M, Brismar TB, 
Ripsweden J, Barany P, Johnson RJ, Stenvinkel P. Copeptin is independently associated with 
vascular calcification in chronic kidney disease stage 5. BMC Nephrol. 2020 Feb 7;21(1):43.  
Dai L, Debowska M, Lukaszuk T, Bobrowski L, Barany P, Söderberg M, Thiagarajan D, 
Frostegård J, Wennberg L, Lindholm B, Qureshi AR, Waniewski J, Stenvinkel P. Phenotypic 
features of vascular calcification in chronic kidney disease. J Intern Med. 2020 Apr;287(4):422-
434.  
Iseri K, Qureshi AR, Dai L, Ripsweden J, Heimbürger O, Barany P, Bergström I, Stenvinkel 
P, Brismar TB, Lindholm B. Bone mineral density at different sites and 5 years mortality in 
end-stage renal disease patients: A cohort study. Bone. 2020 Jan; 130:115075.  
Debowska M, Dai L, Wojcik-Zaluska A, Poleszczuk J, Zaluska W, Lindholm B, Waniewski 
J. Association between Biomarkers of Mineral and Bone Metabolism and Removal of Calcium 
and Phosphate in Hemodialysis. Blood Purif. 2020;49(1-2):71-78.  
Dai L, Watanabe M, Qureshi AR, Mukai H, Machowska A, Heimbürger O, Barany P, 
Lindholm B, Stenvinkel P. Serum 8-hydroxydeoxyguanosine, a marker of oxidative DNA 
damage, is associated with mortality independent of inflammation in chronic kidney disease. 
Eur J Intern Med. 2019 Oct; 68:60-65.  
 
 47 
Dai L, Qureshi AR, Witasp A, Lindholm B, Stenvinkel P. Early Vascular Ageing and Cellular 
Senescence in Chronic Kidney Disease. Comput Struct Biotechnol J. 2019 Jun 18; 17:721-729.  
de Almeida Alvarenga L, Borges NA, Moreira LSG, Resende Teixeira KT, Carraro-Eduardo 
JC, Dai L, Stenvinkel P, Lindholm B, Mafra D. Cranberries - potential benefits in patients with 
chronic kidney disease. Food Funct. 2019 Jun 19;10(6):3103-3112.  
Mukai H, Dai L, Chen Z, Lindholm B, Ripsweden J, Brismar TB, Heimbürger O, Barany P, 
Qureshi AR, Söderberg M, Bäck M, Stenvinkel P. Inverse J-shaped relation between coronary 
arterial calcium density and mortality in advanced chronic kidney disease. Nephrol Dial 
Transplant. 2020 Jul 1;35(7):1202–1211.  
Mukai H, Svedberg O, Lindholm B, Dai L, Heimbürger O, Barany P, Anderstam B, Stenvinkel 
P, Qureshi AR. Skin autofluorescence, arterial stiffness and Framingham risk score as 
predictors of clinical outcome in chronic kidney disease patients: a cohort study. Nephrol Dial 
Transplant. 2019 Mar 1;34(3):442-448.  
Alves FC, Sun J, Qureshi AR, Dai L, Snaedal S, Bárány P, Heimbürger O, Lindholm B, 
Stenvinkel P. The higher mortality associated with low serum albumin is dependent on 
systemic inflammation in end-stage kidney disease. PLoS One. 2018 Jan 3;13(1): e0190410.  
Dai L, Mukai H, Lindholm B, Heimbürger O, Barany P, Stenvinkel P, Qureshi AR. Clinical 
global assessment of nutritional status as predictor of mortality in chronic kidney disease 
patients. PLoS One. 2017 Dec 6;12(12): e0186659.   
Dai L, Golembiewska E, Lindholm B, Stenvinkel P. End-Stage Renal Disease, Inflammation 
and Cardiovascular Outcomes. Contrib Nephrol. 2017; 191:32-43.  
Other Manuscripts 
Dai L, Schurgers LJ, Shiels PG, Stenvinkel P. Can studies of nature help us understand the 
mechanisms of ageing in burden of life style diseases? Submitted 
 
International Scientific Congress 
Oral presentation as first author of accepted abstracts 
Aortic valve calcium associates with all-cause mortality in patients with end-stage kidney 
disease, European Cooperation in Science and Technology (COST) meeting: The Complex 
Pathophysiology of Cardiovascular Calcification, Antwerp, Belgium, Dec 2-3, 2019 
Sevelamer associates with vitamin K and microbial metabolism in ESKD, Annual Meeting of 




Oxidative DNA damage associates with clinical outcome in prevalent PD patients, 14th 
European Peritoneal Dialysis Meeting (EuroPD) 2019, Ljubljana, Slovenia, May 3-5, 2019  
Serum osteoprotegerin associates with vascular calcification in ESKD, XIX International 
Congress on Nutrition and Metabolism in Renal Disease (ICRNM 2018), Genova, Italy, June 
26-30, 2018 
Inflammation modifies the mortality predictive capacity of oxidative DNA damage in CKD 
patients, 54th European Renal Association-European Dialysis and Transplant Association 
(ERA-EDTA) Congress, Madrid, Spain, June 3-6, 2017 
Poster presentation as first author of accepted abstracts 
Matrix Gla protein and premature vascular calcification in patients with end-stage renal 
disease, 57th ERA-EDTA Fully Virtual Congress, June 6-9, 2020 
Predictors of vascular calcification in ESKD, 56th ERA-EDTA Congress, Budapest, Hungary, 
June 13-16, 2019 
Osteoprotegerin associates with microbiota-derived phenylacetylglutamine in CKD, ASN 
Kidney Week 2018, San Diego, CA, USA, Oct 23-28, 2018 
Subjective global assessment of nutritional status associates with all-cause mortality in CKD 
patients, World Congress of Nephrology (WCN) 2017, Mexico City, Mexico, April 21-25, 
2017 
 
 
 
 
 
